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Study descriptions 
 
British 1958 Birth Cohort 
 
The British 1958 Birth Cohort (1958 BC) is a longitudinal population based cohort study that 
includes all births during one week in March in 1958 in England, Scotland and Wales 
1
. 
Approximately 17,000 participants were recruited at birth and were subsequently followed up 
at ages 7, 11, 16, 23, 33, 42 and 45 years. At each follow-up, information on socioeconomic 
status, health and development, and familial and education factors were obtained. At 33 and 
42 years, diet, lifestyle and occupational factors were also collected. Information on smoking 
status, asthma and hay fever were collected at the age of 42. At 45 years of age, 11,971 
participants currently living in Britain were invited to take part in a biomedical survey, of 
whom 9,377 (78%) filled in a questionnaire and 8,302 (89%) also provided a blood sample, 
in which serum IgE concentration were measured and DNA were extracted for genotyping.  
 
Genotyping 
Genetic information was obtained from blood samples collected at 45 years, through two sub-
studies from case-control studies that had used the 1958BC as a source for population 
controls: 3000 samples were randomly selected as part of the Wellcome Trust Case Control 
Consortium (WTCCC2 
2
) and 2592 distinct samples were randomly selected as part of the 
Type 1 Diabetes Genetics Consortium (T1DGC 
3
). The WTCCC2 samples were genotyped 
on the Affymetrix 6.0 platform, whereas T1DGC samples were genotyped using the Illumina 
Infinium 550 K chip. The SNP rs16969968 was imputed both in T1DGC and in WTCCC2, 
with average posterior call rate >0·99 in both studies.  
 
Hay fever, asthma, and allergic sensitization 
At age 42, participants were asked whether they had ever had hay fever. There were 3·20% 
missing hay fever data (percentage of participants with missing information on the outcome 
among those with the genotyping information). At age 42, participants were asked whether 
they had ever had asthma. There were 3·22% missing asthma data (percentage of participants 
with missing information on the outcome among those with the genotyping information). 
Allergic sensitization was defined as specific IgE ≥0·30 kU/l in blood serum for any of the 
following 3 inhalant allergens including dust, cat and grass. Of note, specific IgE were only 
measured if total IgE was greater than 30 kU/l. There 3·33% missing data regarding allergic 
sensitization (percentage of participants with missing information on the outcome among 
those with the genotyping information). 
 
Smoking status 
Cigarette smoking was recorded at age 42 by Computer Aided Personal Interviewing, and 
was classified as never, ex- or current smoker.  Reports of never smoking were verified using 
data from surveys at ages 23 and 33. Number of cigarettes smoked per day at 42 years was 
also reported for current smokers. Pipe and cigar smokers were excluded from analyses.  
In the current analyses, we included 4,882 participants with rs1051730 genotype, allergic 
respiratory disease, and smoking data available.  
 
Ethics 
Written consent was obtained from participants for the use of information in medical studies. 
The 45-year biomedical survey and genetic studies were approved by the South-East Multi- 
Centre Research Ethics Committee (ref: 01/1/44) and the joint UCL/UCLH Committees on 
the Ethics of Human Research (Ref: 08/H0714/40). 
7 
 
 
Funding and acknowledgements 
Data collection was funded by grant no. G0000934 from the UK Medical Research Council 
and cell-line creation by Wellcome Trust grant 068545/Z/02. This research used resources 
provided by the Type 1 Diabetes Genetics Consortium, a collaborative clinical study 
sponsored by the National Institute of Diabetes and Digestive and Kidney Diseases 
(NIDDK), National Institute of Allergy and Infectious diseases, National Human Genome 
Research Institute, National Institute of Child Health and Human Development, and Juvenile  
Diabetes Research Foundation International (JDRF) and supported by U01DK062418. This 
study makes use of data generated by the Wellcome Trust Case-Control Consortium. A full 
list of investigators who contributed to generation of the data is available from the Wellcome 
Trust Case-Control Consortium website. Funding for the project was provided by the 
Wellcome Trust under award 076113. Support was provided by the National Institute for 
Health Research Biomedical Research Centre at Great Ormond Street Hospital for Children 
NHS Foundation Trust and University College London. 
 
Additional information 
The analyses are adjusted for principal component. The observational or genetic data have 
previously been published. 
 
 
ALSPAC 
 
The Avon Longitudinal Survey of Parents and Children is a prospective cohort study which 
recruited pregnant women residing in Avon, United Kingdom, with expected dates of 
delivery between 1 April 1991 and 31 December 1992. Full details of the study recruitment 
and methodology have been published previously 
4,5
. A total of 14,541 pregnancies were 
included in the initial sample, resulting in 14,062 live births and 13,988 children who were 
alive at one year of age. Detailed information on mothers and their partners (during and after 
pregnancy) and the children (since birth) has been collected from self-report questionnaires 
and attendance at clinics. Please note that the study website contains details of all the data 
that is available through a fully searchable data dictionary 
(http://www.bristol.ac.uk/alspac/researchers/data-access/data-dictionary/). 
 
Funding and acknowledgements 
The UK Medical Research Council and the Wellcome Trust (Grant ref: 092731) and the 
University of Bristol provide core support for ALSPAC. The genetic data for the ALSPAC 
mothers were funded by a grant from the Wellcome Trust (WT088806). Funding from British 
Heart Foundation, Cancer Research UK, Economic and Social Research Council, Medical 
Research Council, and the National Institute for Health Research, under the auspices of the 
UK Clinical Research Collaboration, is gratefully acknowledged. This work was supported 
by the Wellcome Trust (grant number 086684) and the Medical Research Council (grant 
numbers MR/J01351X/1, G0800612, G0802736, MC_UU_12013/1, MC_UU_12013/6). We 
are extremely grateful to all the families who took part in this study, the midwives for their 
help in recruiting them, and the whole ALSPAC team, which includes interviewers, computer 
and laboratory technicians, clerical workers, research scientists, volunteers, managers, 
receptionists and nurses.  
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ALSPAC Mothers 
 
Genotyping  
Rs1051730 was directly genotyped as part of the genomewide SNP genotyping using the 
Illumina human660W-quad array. Genotypes were called with Illumina GenomeStudio. 
PLINK (v1.07) was used to carry out quality control measures on an initial set of 10,015 
subjects and 557,124 directly genotyped SNPs. A total of 8,340 subjects and 526,688 SNPs 
passed quality control filters. Further details of the genotyping methods have been published 
previously 
6
. SNPs with more than 5% missingness were removed during quality control. 
 
Hay fever, asthma, and allergic sensitization 
Self-reported hay fever in the mothers was evaluated in a questionnaire completed when the 
study child was 97 months old. The mothers were asked “Have you ever had any of the 
following problems: hay fever. The choices were “Yes- had it recently (in the past year)”,  
“Yes, in the past, not recently”, or “No, never”. If the mothers had had hay fever recently or 
in the past, they were classified as having hay fever. If they answered never having had hay 
fever, they were classified as not having hay fever. Asthma was evaluated in the same way. 
The mothers were asked “Have you ever had any of the following problems: asthma. The 
choices were “Yes- had it recently (in the past year)”, “Yes, in the past, not recently”, or “No, 
never”. If the mothers had had asthma recently or in the past, they were classified as having 
asthma. If they answered never having had asthma, they were classified as not having asthma. 
Allergic sensitization was not determined. 
   
Smoking status 
The mothers’ self-reported smoking status was also evaluated in a questionnaire sent out 
when their participating children were 97 months old (on average). Women were asked 
whether they had ever smoked and whether they were currently smokers. Former and current 
smokers who reported not being daily smokers were excluded from the analyses. No 
questions were asked about cigar or pipe smoking. Smoking heaviness (cigarettes per day) 
was reported as a continuous variable. In the current analyses, we included 4,834 participants 
with rs1051730 genotype, allergic respiratory disease and smoking data available. 
 
Ethics 
Ethics approval for the study was obtained from the ALSPAC Ethics and Law Committee 
and the Local Research Ethics Committee.  
 
Additional information 
The analyses are not adjusted for principal component. The associations have not been 
published before. 
 
 
ALSPAC Children 
 
Genotyping  
Participants (N=9,912) were genotyped using the Illumina HumanHap550 quad genome-wide 
SNP genotyping platform by 23andMe subcontracting the Wellcome Trust Sanger Institute, 
Cambridge, UK and the Laboratory Corporation of America, Burlington, NC, USA. 
Individuals were excluded from further analysis on the basis of having incorrect gender 
assignments; minimal or excessive heterozygosity, disproportionate levels of individual 
missingness (>3%); evidence of cryptic relatedness (>10% IBD) and being of non-European 
9 
 
ancestry. SNPs with more than 5% missingness were removed during quality control. After 
quality control, 8,365 unrelated individuals were available for analysis. 
 
 
Hay fever, asthma, and allergic sensitization  
Hay fever and asthma were evaluated when the participants were 18 years old. They 
completed a questionnaire with the question: “Have you ever had hay fever?”. Likewise, 
participants completed a questionnaire with the question: “Have you ever had asthma?”. 
Allergic sensitization was not determined. 
 
Smoking status 
At the age of 18 years, participants were asked about their lifetime smoking behaviour. From 
these, two categories of smoking status were created: never smokers and current daily 
smokers. Never smokers reported never having tried a cigarette in their lifetime and current 
daily smokers smoked at least one cigarette per day. Individuals reporting less frequent 
smoking were excluded from analyses. In the current analyses, we included 1,549 
participants with rs1051730 genotype, allergic respiratory disease and smoking data 
available. 
 
Ethics 
Ethics approval for the study was obtained from the ALSPAC Ethics and Law Committee 
and the Local Research Ethics Committee.  
 
Additional information 
The analyses are not adjusted for principal component. The associations have not been 
published before. 
 
 
COPSAC2000 
 
The Copenhagen Prospective study on Asthma in Childhood (COPSAC2000) cohort is a 
population based single-center prospective clinical birth cohorts consisting of 411 children 
with phenotypic and genotypic information available in their parents. The children in the 
COPSAC2000-cohort were born to asthmatic mothers enrolled from the greater Copenhagen 
area in the period from August 1998 to December 2001. Non-missing phenotype data (from 
questionnaires or Doctors diagnosis) for parents of COPSAC2000 cohort (smoking, asthma, 
dermatitis, and allergic sensitization) and genotype data constituted 543 participants for the 
current study. 
 
Genotyping 
Genotyping of 951,117 genetic markers was carried out on the Illumina Infinium 
HumanOmniExpressExome bead chip at the AROS Applied Biotechnology AS center, in 
Aarhus, Denmark. Genotypes were called with Illumina's Genome Studio software. We 
excluded individuals with gender miss-matches, genetic duplicates, outlying heterozygosity 
>0·27 and <0·037, and those individuals not clustering with the CEU individuals (Utah 
residents with ancestry from northern and Western Europe) through a multi-dimensional 
clustering analyses (MDS) seeded with individuals from the International Hap Map Phase 3. 
SNP data was extracted from the Genome wide array data for the current study and the 
genotyping call rate was 99.8%. 
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Hay fever, asthma, and allergic sensitization 
Evaluation of hay fever, asthma and allergic sensitization was done (an average) of 4 years 
before child birth. Participants with a doctor diagnosed hay fever or a positive answer to the 
question: “Have you ever had hay fever?” were considered to have hay fever. Participants 
with a doctor-diagnosed asthma were considered to have asthma. The serum levels were 
tested for IgE specificity, and allergic sensitization was defined as serum specific IgE 
positivity against allergens. 
 
Smoking status 
Smoking information was collected 2 years after child birth. Participants were divided into 
smokers and non-smokers since there was no information on former smoking. There was also 
no information on smoking heaviness. 
 
Ethics 
The study was conducted in accordance with the guiding principles of the Declaration of 
Helsinki and was approved by the Local Ethics Committee (COPSAC2000: KF 01-289/96, 
COPSAC2010: H-B-2008-093), and the Danish Data Protection Agency (COPSAC2000: 
2008-41-1754, COPSAC2010: 2008-41-2599). Both parents gave written informed consent 
before enrolment. 
 
Funding and acknowledgements 
COPSAC is funded by private and public research funds all listed on www.copsac.com. The 
Lundbeck Foundation (Grant no R16-A1694); The Danish Ministry of Health (Grant no 
903516); Danish Council for Strategic Research (Grant no 0603-00280B); The Danish 
Council for Independent Research (Grant no 10-082884 and271-08-0815); The Capital 
Region Research Foundation (No grant number) and NIH-NHLBI R01 HL129735 have 
provided core support for COPSAC. We express our gratitude to the children and families of 
the COPSAC cohorts for their support and commitment to our studies and acknowledge and 
appreciate the unique efforts of the COPSAC research team. 
  
 
Additional information 
The analyses are not adjusted for principal component. The observational or genetic data 
have previously been published 
7
. 
 
 
The Dan-Monica10 study 
 
In 1982–1984, a random sample of 4807 participants from the referral area of Glostrup 
County Hospital, Copenhagen, was invited to participate in the Danish MONICA I health 
survey 
8
. The study was a part of an international World Health Organization (WHO) co-
ordinated study, MONItoring of trends and determinants in CArdiovascular Diseases 
(MONICA). The sample was selected to represent an equal number of men and women born 
in 1922, 1932, 1942 or 1952 (age 30, 40, 50 and 60 years). A total of 226 Individuals, who 
were not of Danish nationality, were excluded. Of the remaining 4581 Danes, 3608 
participated (79%). We used data from a follow-up examination performed in 1993-1994, 
called Dan-MONICA10. Since the first examination, 428 subjects had died and 23 had 
moved and could not be reached. The remaining 4130 Danes were invited to a new 
examination, when the participants were aged 41, 51, 61, or 71 years old. A total of 2656 
(64%) participated in the Dan-MONICA10 follow-up study. The health examinations took 
11 
 
place a Research Centre for Prevention and Health, Glostrup. Participants completed a self-
administered questionnaire on cardiovascular risk factors, medical history and lifestyle habits, 
including smoking and physical activity. A physical examination was performed by trained 
staff. 
 
Hay fever, asthma, and allergic sensitization  
Hay fever was defined as a positive answer to the question: “Has a doctor ever told you that 
you had allergic hay fever?” Asthma was defined as a positive answer to the question: “Has a 
doctor ever told you that you had asthma?”Allergic sensitisation, allergic sensitization, was 
defined by determination of serum specific IgE as described in previous studies 
9-12
. In the 
Monica1 study, serum specific IgE positivity was tested using the ADVIA Centaur Allergy 
Screen assay (Bayer HealthCare Diagnostics division, Tarrytown, N.Y., USA) 
13
 that is a 
multi-allergen assay to detect specific serum IgE antibodies to 19 common inhalant allergens. 
Allergic sensitization was defined as one or more positive results according to the 
manufacturer’s instructions.  
 
Smoking status 
Information on smoking status was collected by a self-administered questionnaire to be filled 
in at home prior to the health examination. Smoking status was recorded as never, former, 
occasional (<1 cigarette, cheroot, cigar, or pipe per day) and daily smokers. Occasional 
smokers as well as daily smokers, who exclusively smoke cheroots, cigars, or pipe, were 
excluded from all analyses. Smoking heaviness among daily smokers was recorded as 
number of cigarettes per day. In the current study, we included 2,054 participants between 41 
and 73 years of age. 
 
Genotyping 
Genotyping of rs1051730 was performed using KBiosciences allele-specific PCR (KASPar) 
(KBioscience, Hoddesdon, UK). 
 
Ethics 
Ethics approval was given by the local research ethics committee. All participants gave 
written consent and the study was conducted in accordance with the Second Helsinki 
Declaration.  
 
Funding and acknowledgements 
The Dan-MONICA10  was sponsored by The Danish Heart Foundation; the Danish Medical 
Research Council; The Danish Hospital Foundation of Medical Research, region of 
Copenhagen, the Faroe Islands and Greenland; The Danish Health Insurance Foundation; The 
Foundation of E. & M. Wedel-Wedellsborg; Landsforeningen til Bekæmpelse af 
Kredsløbssygdomme; The Augustinus Foundation; The Becket Foundation; and The 
Foundation of senior registrar J. & L. Boserup.  
 
Additional information 
The analyses are not adjusted for principal component. The genetic data used in this study 
have not previously been published. 
 
 
ELSA 
The English Longitudinal Study of Ageing (ELSA) is a population based national cohort of 
participants (48% men) aged over 50 years recruited from the Health Surveys for England in 
12 
 
1998, 1999 and 2001 as previously described 
14
. The sample has been followed up every 2 
years and data have been collected via computer-assisted personal interviews and self-
completion questionnaires. A wide range of phenotypic measures relevant to ageing are 
available. These measures were done at Wave 0 of the study (1998, 1999 and 2001) and at 
follow up (2004/5). Data on health behaviors and a wide range of health outcomes are 
available. Nearly all participants (97%) have agreed to let us collect other register based data 
which allows for the assessment of health outcomes and cause specific mortality. More 
information can be found at http://www.ifs.org.uk/elsa/. 
 
Genotyping 
In Wave 2 (2004/2005) of the study, 5,633 participants provided blood samples for DNA 
extraction.  Genotyping was performed by KBioscience using in-house KaSPAR technology.   
 
Hay fever, asthma, and allergic sensitization 
Whether the participants had asthma or not was evaluated at wave 1, where they were asked: 
“Has a doctor ever told you that you have/have had any of the following conditions 
(asthma)?“. Hay fever and allergic sensitization were not determined. 
 
Smoking status 
Individuals were classified as current smokers if they reported smoking at least one cigarette 
per day or at least one gram of tobacco per day on weekdays. Former smokers were 
individuals who reported ever having smoked cigarettes but who were not current smokers. 
Never smokers were individuals who had never reported smoking cigarettes. Current or 
former pipe and cigar smokers who did not also smoke cigarettes were excluded from all 
analyses. In the current analyses, we included 5,263 participants with rs16969968 genotype 
and smoking data available. 
 
Ethics 
ELSA has been approved by the National Research Ethics Service and all participants have 
given informed consent. 
 
Funding and acknowledgements 
ELSA is funded by the National Institute on Aging in the US (R01 AG017644; 
R01AG1764406S1) and by a consortium of UK Government departments (including: 
Department for Communities and Local Government, Department for Transport, Department 
for Work and Pensions, Department of Health, HM Revenue and Customs and Office for 
National Statistics). 
 
Additional information 
The analyses are not adjusted for principal component. The results have not been published 
previously. 
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FINRISK 
 
The National Finland Cardiovascular Risk Study (FINRISK) is a large population survey on 
risk factors of  non-communicable diseases in Finland 
15
. Every five years since 1972, area, 
sex and age stratified random samples of population have been drawn from the Population 
Register. In these analyses, data from FINRISK 1992, 1997, 2002 and 2007 surveys were 
used.  Age range of the participants was from 25 to 64 years in study years 1992 and 1997 
and from 25 to 74 years in study years 2002 and 2007. Surveys have included a self-
administered questionnaire, physical examination and blood draw for laboratory analyses and 
extraction of DNA.  
 
Genotyping 
DNA was derived from whole blood samples, which were frozen immediately at the clinical 
study sites. The samples were transferred to the National Institute of Health and Welfare, 
where the DNA was extracted. Genotyping of rs16969968 (CHRNA5 D398N) was done 
under standard protocols of iPLEX Gold technology on the MassARRAY System 
(Sequenom, San Diego, CA, USA). The success rate was >0·99 and it was in HWE. Minor 
allele frequency was 0·32. 
 
Hay fever, asthma, and allergic sensitization 
Diagnoses of hay fever and asthma were based on self-report. Participants who answered 
“last week”, “last month” or “last year” to the question: “When have you last used hay fever 
medication” were classified as having hay fever. Likewise, participants with a positive 
answer to the question: “Has a doctor ever told you that you had asthma?” were classified as 
having asthma. Data on hay fever was available in FINRISK 1997, 2002 and 2007 surveys, 
whereas asthma data was available in FINRISK 1992 survey as well. Allergic sensitization 
was not determined. 
 
Smoking status 
In the same questionnaire, respondents were asked whether they had ever smoked. Those 
stating that they had never smoked were categorized as never smokers and skipped the other 
smoking-related questions. Ever smokers were defined as those who had smoked at least 100 
cigarettes in their lifetime. More questions were used to classify ever smokers as current and 
former smokers. Former smokers reported having been either regular or occasional smokers 
but were not smoking currently. For the current analyses, only those who had quit over 6 
months ago were included in the former smoker category. Current smokers reported regular 
or daily smoking having smoked on the day of the assessment or the previous day.  Exclusive 
pipe or cigar smokers were excluded from all analyses. In order to create a variable for 
smoking quantity the participants were asked to indicate the average number of both 
manufactured and self-rolled cigarettes they smoked or had smoked per day before quitting. 
Manufactured and self-rolled cigarettes were totalled for the analysis. 
 
Ethics 
Surveys have obtained permissions from the local Ethics Committees that have varied over 
time, such as the Coordinating Ethics Committee for the Uusimaa Hospital District in 2007.  
From 1997 onwards a written informed consent has been obtained from each participant. 
 
Funding 
This study was supported by the Academy of Finland Center of Excellence in Complex 
Disease Genetics (grant numbers 213506, 129680), the Academy of Finland (grant numbers 
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139635, 129494, 136895, 263836 and 141054), the Sigrid Juselius Foundation, and 
ENGAGE – European Network for Genetic and Genomic Epidemiology, FP7-HEALTH-F4-
2007, grant agreement number 201413. Finnish Foundation for Cardiovascular Research. 
 
Additional information 
The analyses are not adjusted for principal component. The data concerning the smoking 
associated SNP and allergy have not been published previously. 
 
 
GOYA Females  
The GOYA females consist of mothers from a birth cohort randomly selected according to 
body mass index (BMI) distribution. The GOYA females were derived from the Danish 
genome-wide association study GOYA (Genomics of Overweight in Young Adults), nested 
within the Danish National Birth Cohort (DNBC) 
16,17
. The Danish National Birth Cohort 
(DNBC) is a collection of data on 92,274 pregnant women recruited between 1996 and 2002, 
from their first antenatal visit to their general practitioner. Women participated in four 
telephone interviews (16 and 30 weeks gestation and 6 and 18 months after birth) and in a 
questionnaire-based follow-up 7 years after birth. They also provided two blood samples 
during pregnancy. The GOYA females used in this study were drawn as a random cohort 
sample from the 67,863 women within the DNBC who provided information about pre-
pregnancy BMI, gave birth to a live born singleton infant and provided a blood sample during 
pregnancy. This comprised 2,542 women.  
 
Genotyping 
Genotyping of rs1051730 was carried out on the Illumina Human610-Quad v1.0 BeadChip 
(545,350 SNPs) at the Centre National de Génotypage (CNG), Evry, France. Call rate>0·99. 
 
Hay fever, asthma, and allergic sensitization 
Women were asked at app. 16 weeks gestation if they had ever had allergic rhinitis diagnosed 
by a doctor (0·6% missing). Women were asked at app. 16 weeks gestation if they had ever 
had asthma diagnosed by a doctor (5·3% missing). Allergic sensitization was not determined. 
 
Smoking status  
Women were asked about their present smoking status and any smoking during pregnancy at 
app. 16 weeks of gestation. Women were therefore classified as ’current’ (current + any 
smoking in pregnancy) or ’never/former’ smokers (no smoking at any time in pregnancy). In 
the current analyses, there were 2,016 participants with data on rs1051730 genotype and 
smoking habits and of these, 2,009 women had information on asthma and 1,897 had 
information on hay fever available. 
 
Ethics 
The study was approved by the regional scientific ethics committee and by the Danish Data 
Protection Board. All participants provided written informed consent. 
 
Funding and acknowledgements 
GOYA (Genomics of Obesity in Young Adults) was sampled as a case-cohort study within 
the Danish National Birth Cohort. The establishment of this cohort was based on a major 
grant from the Danish National Research Foundation. Additional support for the Danish 
National Birth Cohort was obtained from the Pharmacy Foundation, the Egmont Foundation, 
the March of Dimes Birth Defects Foundation and the Augustinus Foundation. Genotyping 
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for the GOYA Study was funded by the Wellcome Trust (Grant ref: 084762MA). The MRC 
Integrative Epidemiology Unit is supported by the Medical Research Council 
(MC_UU_12013/1-9) and the University of Bristol. 
 
Additional information 
The analyses are not adjusted for principal component. The data concerning the smoking 
associated SNP and allergy has not been published previously. 
 
 
GOYA Males  
 
Genomics of Overweight in Young Adults (GOYA) males is a longitudinal case-cohort 
(obese, non-obese) study comprising a randomly (1%) selected control group and all 
extremely overweight men identified among 362,200 Caucasian men examined at the mean 
age of 20 years at the draft boards in Copenhagen and its surrounding areas during 1943–
1977. Obesity was defined as 35% overweight relative to a local standard in use at the time 
(mid 1970’s), corresponding to a BMI ≥31·0 kg/m2, which proved to be above the 99th 
percentile. All of the obese and 50% of the random sampled controls, who were still living in 
the region, were invited to a follow-up survey in 1992–94 at the mean age of 46 years, at 
which time the blood samples were taken and genotyping were performed for a total of 673 
extremely overweight and 792 controls. With a sampling fraction of 0·5% (50% of 1%), the 
controls represent about 158,000 men among whom the case group was the most obese. In 
the current study, information from cohort part comprising 789 individuals with non-missing 
data was utilized. 
 
Genotype 
Genome-wide genotyping on the Illumina 610 k quad chip was carried out at the Centre 
National de Ge´notypage (CNG), Evry, France. We excluded SNPs with minor allele 
frequency, 1%, 0.5% missing genotypes or which failed an exact test of Hardy-Weinberg 
equilibrium (HWE) in the controls. We also excluded any individual who did not cluster with 
the CEU individuals (Utah residents with ancestry from northern and western Europe) in a 
multidimensional scaling analysis seeded with individuals from the International HapMap 
release 22. Rs1051730 was extracted from the GWAS dataset with a call rate of 99·9%. 
 
Hay fever, asthma, and allergic sensitization 
Asthma was evaluated by questionnaire with the question: ”Does food, medicine, or grass 
give you asthma?” Hay fever was evaluated by the question: “Does food, medicine or grass 
give you hay fever?” Allergic sensitization was not determined. 
 
Ethics 
The study was approved by the regional scientific ethics committee and the Danish Data 
Protection Board with consent from the participants.  
 
Funding and acknowledgements 
The GOYA study was conducted as part of the activities of the Danish Obesity Research 
Centre (DanORC, www.danorc.dk) and The MRC centre for Causal Analyses in 
Translational Epidemiology (MRC CAiTE). The genotyping for GOYA was funded by the 
Wellcome Trust (WT 084762). GOYA is a nested study within The Danish National Birth 
Cohort which was established with major funding from the Danish National Research 
Foundation. Additional support for this cohort has been obtained from the Pharmacy 
16 
 
Foundation, the Egmont Foundation, The March of Dimes Birth Defects Foundation, the 
Augustinus Foundation, and the Health Foundation. TSA was supported by the Gene Diet 
Interactions in Obesity (GENDINOB, www.gendinob.dk ) postdoctoral fellowship grant. LP 
is funded by an MRC Population Health Scientist Fellowship (MR/J012165/1). 
 
Additional information 
The analyses are not adjusted for principal components, but ethnic outliers and related 
individuals were already excluded during post genotyping quality control. Some data were 
previously published 
16
. 
 
 
Health2006 
 
The Health2006 study took place during 2006-2008 and consisted of a random sample of 
7,931 Danish (Danish nationality and born in Denmark) men and women aged 18-69 years 
invited to participate in a health examination 
18
. A total of 3,471 (43·8%) participated. 
Potential participants living in the Copenhagen area were identified in the central Danish 
Civil Registration System, and then recruited by invitation. The aim was to investigate the 
prevalence and risk factors of chronic diseases such as mental health, asthma, allergies, 
cardiovascular disease, and diabetes.  
 
Genotyping 
Blood samples were taken from all participants as part of their health examination. The buffy 
coat was frozen for DNA extraction, and later genomic DNA was extracted using a Qiagen 
AutoPure LS system. Genotyping was performed using KBiosciences allele-specific PCR 
(KASPar) (KBiosciences, Hoddesdon, UK). The call rate for this SNP (rs1051730) was > 
99·2%. No errors were observed in 370 duplicate samples.  
 
Hay fever, asthma, and allergic sensitization 
We used the ADVIA Centaur sIgE assay (Bayer Corporation, New York, NY) to test serum 
specific IgE to mite (Dermatophagoides [D.] pteronyssinus), grass, cat, and birch
19
. The 
specific IgE analysis was positive if the measurement was ≥0·35 kU/l. Allergic sensitization, 
allergic sensitization, was defined as one or more positive tests for specific IgE against the 
allergens. Classification of hay fever and asthma was done by the questions: ”Has a doctor 
ever told you that you had/have hay fever?” and ”Has a doctor ever told you that you 
had/have asthma”. 
  
Smoking status 
Information on smoking status was collected by a self-administered questionnaire to be filled 
in at home prior to the health examination. Smoking status was recorded as never, former, 
occasional (<1 cigarette, cheroot, cigar, or pipe per day) and daily smokers. Occasional 
smokers as well as daily smokers smoking exclusively cheroots, cigars, or pipe were 
excluded from all analyses. Smoking heaviness among daily smokers was recorded as 
number of cigarettes per day. In the current analyses, we included 3143 participants with 
rs1051730 genotype, allergic respiratory disease and smoking data available.  
 
Ethics 
The Health2006 study was approved by the Ethical Committee of Copenhagen (KA-
20060011) and the Danish Data Protection Agency. Informed written consent was obtained 
from all participants.. 
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Funding and acknowledgements 
The Health2006 study was financially supported by grants from the Velux Foundation; the 
Danish Medical Research Council, Danish Agency for Science, Technology and Innovation; 
the Aase and Ejner Danielsens Foundation; ALK-Abello´ A/S (Hørsholm, Denmark), Timber 
Merchant Vilhelm Bangs Foundation, MEKOS Laboratories (Denmark) and Research Centre 
for Prevention and Health, the Capital Region of Denmark. 
 
Additional information 
The analyses are not adjusted for principal component. The data concerning the smoking 
associated SNP and allergy has not been published previously. 
 
 
Health2008 
 
The Health2008 study is a study of health and chronic disease initiated in 2008 and 
completed in 2009 
20-22
. Participants were recruited from the Danish Central Personal 
Register as random samples of the background population living in the Western part of the 
Copenhagen Region 
22
. The total of 2218 persons 30-60 years of age was invited. Pregnant 
women, persons with known diabetes, chronic obstructive pulmonary disease, cardiovascular 
disease, hypertension, a history of blood clots, or unable to participate in physical activities 
such as climbing stairs were excluded from the study. Thus, a total of 795 participated 
(participation rate 36%). All studies included comprehensive questionnaire and interview 
data  as well as clinical and biochemical data 
22
.  
 
Genotyping 
DNA was extracted from blood samples taken from all participants as part of their health 
examination. Genotyping was performed with the Illumina Human Exome BeadChip (version 
1.2) using the Illumina HiScan (Illumina, San Diego, CA). Genotypes were called using the 
genotyping module (version 1.9.4) of GenomeStudio software (version 2011.1; Illumina). 
The call rate for this SNP (rs16969968) was > 99%. 
 
Hay fever, asthma, and allergic sensitization 
Classification of hay fever and asthma was done by the questions: ”Has a doctor ever told 
you that you had hay fever?” and ”Has a doctor ever told you that you had asthma”. In the 
Health2008 study, we used the ADVIA Centaur sIgE assay (Bayer Corporation, New York, 
NY) to test serum specific IgE to mite (Dermatophagoides [D.] pteronyssinus), grass, cat, and 
birch. Allergic sensitization was defined as serum specific IgE positivity to one or more of 
the tested allergens. 
 
Smoking status 
Information on smoking status was collected by a self-administered questionnaire to be filled 
in at home prior to the health examination. Smoking status was recorded as never, former, 
occasional (<1 cigarette, cheroot, cigar, or pipe per day) and daily smokers. Occasional 
smokers as well as daily smokers smoking exclusively cheroots, cigars, or pipe were 
excluded from all analyses. Smoking heaviness among daily smokers was recorded as 
number of cigarettes per day. In the current analyses, we included 618 participants with 
rs16969968 genotype, allergic sensitization and smoking data available.  
 
Ethics 
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The study was approved by the Ethics Committee of Copenhagen and the Danish Data 
Protection Agency. We followed the recommendations of the Declaration of Helsinki, and 
each participant gave informed written consent. 
 
Funding and acknowledgements 
This work was supported by the Timber Merchant Vilhelm Bang’s Foundation, the Danish 
Heart Foundation (Grant number 07-10-R61-A1754-B838-22392F), and the Health Insurance 
Foundation (Grant number 2012B233). Tea Skaaby was supported by a grant from the 
Lundbeck Foundation (Grant number R165-2013-15410).  
 
Additional information 
The analyses are not adjusted for principal component. The data concerning the smoking 
associated SNP and allergy has not been published previously. 
 
 
HUNT2  
 
The second wave of the HUNT Study in Norway (HUNT 2) took place in 1995-97, where all 
adults aged 20 years and older in Nord Trøndelag County were invited to participate. A total 
of 65,237 (70%) accepted the invitation and gave written informed consent to use the data for 
medical research. The data collection included questionnaires, clinical measurements and 
blood samples (http://www.ntnu.edu/hunt/data/que).  
 
Genotyping  
Altogether 56,664 participants were genotyped for the rs1051730 single nucleotide 
polymorphism variant. DNA was extracted from blood samples for all participants of the 
HUNT 2 study and stored at the HUNT biobank. The rs1051730 polymorphism was 
genotyped at the HUNT biobank using TaqMan genotyping assays (Applied Biosystems, 
Foster City, CA, USA) and performed on an Applied Biosystems 7900HT Fast real-Time 
PCR System using 10 ng of genomic DNA. The call rate cut-off was set to 90%. The 
genotyping success rate was 98·6% and quality score for each individual genotype was >90 
(mean 99·7). Genotype frequencies were in agreement with HapMap data.  
 
Hay fever, asthma, and allergic sensitization 
Hay fever was defined as a confirmative answer to the question: ”Do you have hay fever or 
nasal allergies?” Asthma was defined as a confirmative answer to the question: ”Do you have 
or have you had asthma?”. Allergic sensitization was not determined. 
 
Smoking status 
Smoking status was measured with self-completed questionnaire data with a categorical 
variable, and the participants were classified as never smokers, former smokers or current 
smokers. Current smokers were asked how many cigarettes they smoked per day, the age 
when starting to smoke and possibly age for smoking cessation. Exclusive pipe and/or cigar 
smokers were excluded from the analyses. In the current analyses, we included 43,211 
participants between the ages 19 to 101 years with rs1051730 genotype, allergic respiratory 
disease and smoking data available. 
 
Ethics 
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Use of data in the present study was approved by the Regional Committee for Medical 
Research Ethics (Reference nr. 2013/1127/REK midt). Participants gave written informed 
consent. 
 
Funding and acknowledgements 
Nord-Trøndelag Health Study (The HUNT Study) is a collaboration between HUNT 
Research Centre (Faculty of Medicine, Norwegian University of Science and Technology 
NTNU), Nord-Trøndelag County Council and the Norwegian Institute of Public Health. 
 
Additional information 
The analyses were not adjusted for principal component. Associations between the SNP and 
e.g., lung cancer have previously been published 
23
. 
  
 
Inter99 
 
The Inter99 study is a randomised controlled trial (CT00289237, ClinicalTrials.gov) 
investigating the effects of lifestyle intervention on CVD (N=61,301) 
24
. We used baseline 
data from a random subsample of 12,934 men and women aged approximately 30, 35, 40, 45, 
50, 55, or 65 years invited to participate in a health examination during 1999-2001.  
Participants were living in the Copenhagen area and were identified in the central Danish 
Civil Registration System, and recruited by invitation. Only participants with a Northern 
European origin (Denmark, Norway, Sweden, Iceland, and Faeroe Islands) were included in 
the present study.  
 
Genotyping 
DNA was extracted from blood samples taken from all participants as part of their health 
examination. Genotyping was performed using KBiosciences allele-specific PCR (KASPar) 
(KBiosciences, Hoddesdon, UK). The call rate for this SNP (rs1051730) was > 98·8%. No 
errors were observed in 353 duplicate samples. 
 
Hay fever, asthma, and allergic sensitization 
Asthma was defined as a positive answer to the question: “Has a doctor ever told you that 
you had asthma?” Serum samples were analyzed for specific IgE to mite (D. pteronyssinus), 
grass, cat, and birch by the IMMULITE 2000 Allergy Immunoassay System 
25
. The specific 
IgE analysis was positive if the measurement was ≥0·35 kU/l. Allergic sensitization, allergic 
sensitization, was defined as a positive tests for specific IgE against any of allergens. Hay 
fever was not determined. 
 
Smoking status 
Information on smoking status was collected by a self-administered questionnaire to be filled 
in at home prior to the health examination. Smoking status was recorded as never, former, 
occasional (<1 cigarette, cheroot, cigar, or pipe per day) and daily smokers. Occasional 
smokers as well as daily smokers smoking exclusively cheroots, cigars, or pipe were 
excluded from all analyses. Smoking heaviness among daily smokers was recorded as 
number of cigarettes per day. In the current analyses, we included 4,991 participants with 
rs1051730 genotype, asthma, allergic sensitization, and smoking data available.  
 
Ethics 
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Informed written consent was obtained from all participants. The study was approved by the 
Ethical Committee of Copenhagen. 
 
Funding and acknowledgements 
Data collection in the Inter99 study was supported economically by The Danish Medical 
Research Council, The Danish Centre for Evaluation and Health Technology Assessment, 
Novo Nordisk, Copenhagen County, The Danish Heart Foundation, The Danish 
Pharmaceutical Association, Augustinus foundation, Ib Henriksen foundation and Becket 
foundation.  
 
Additional information 
The analyses are not adjusted for principal component. The data concerning the smoking 
associated SNP and allergy has not been published previously. 
 
 
KORA  
The Cooperative Health Research in the Region of Augsburg (KORA) study is a population 
based case-control study. The study participants were recruited from the third MONICA 
survey (S3) which was conducted in 1994-1995 in Augsburg, Germany. The objective and 
protocols of the MONICA surveys have been previously described 
26
. Briefly, four cross-
sectional health surveys (MONICA S1 to S4) were performed in the population aged 25-74 
years of the city of Augsburg and two surrounding counties. In total, 4856 participants were 
recruited in the S3 survey in 1994/1995. The study used for these analyses is a nested case-
control study comprising 1537 participants, which was performed between September 1997 
and December 1998 and in which cases were defined by sensitization status (SPT/RAST). 
Details of the sampling frame and study design have been published earlier 
27
. 
Genotyping 
The study participants underwent a standardized medical examination including blood draw. 
Genotyping was performed on the Illumina Omni 2.5 and the Illumina Omni Express 
platform. Genotypes were called with Genome Studio and annotated to NCBI build 37. The 
call rate for this SNP (rs1051730) was ≥ 98%. (Before imputation, SNPs with call rates <98% 
were excluded. Imputation was performed with IMPUTE v2.3.0 using the 1000G phase 1 
(v3) reference panel) 
28
. 
  
Hay fever, asthma, and allergic sensitization 
Information on hay fever was requested using a self-administered questionnaire. The 
participants were asked whether hay fever was ever diagnosed by a doctor. Information on 
asthma was requested using a self-administered questionnaire. The participants were asked 
whether asthma was ever diagnosed by a doctor. Allergen specific IgE antibodies to common 
aeroallergens (grass and birch pollen, housedust mite, cat and Cladosporium) were 
determined by the fluorescence enzyme immunoassay technique (CAP-FEIA, Pharmacia, 
Uppsala, Sweden). Allergic sensitization was defined as serum specific IgE sensitivity (≥ 
0·35 kU/l) against at least one inhalant allergen. 
 
Smoking status 
Information on smoking status was collected using a self-administered questionnaire. 
Smoking status was defined based on the following three questions: 1) “Do you currently 
smoke cigarettes?”, 2) “Have you ever smoked?” and 3) “Do you smoke regularly?”  
Current smoker, if the participant answered yes to questions 1) and 3); former smoker, if the 
participant answered no to question 1), but yes to question 2) and never smoker, if the 
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participant answered no to questions 1) and 2). Information on smoking heaviness was 
requested by the question “How many cigarettes per day?”. 
 
Ethics 
The study was approved by the ethics committee of the Bavarian Medical Association, and 
written informed consent was obtained from each participant. 
 
Funding 
The KORA study was initiated and financed by the Helmholtz Zentrum München – German 
Research Center for Environmental Health, which is funded by the German Federal Ministry 
of Education and Research (BMBF) and by the State of Bavaria. Furthermore, KORA 
research was supported within the Munich Center of Health Sciences (MC-Health), Ludwig-
Maximilians-Universität, as part of LMUinnovativ. 
 
 Additional information 
The analyses were not adjusted for principal component. The data has not been published 
before. 
 
 
MIDSPAN Family Study 
 
The Middle-aged Span-of-Life (MIDSPAN) Family Study is an offspring cohort of one of the 
original MIDSPAN cohorts. It is one of four MIDSPAN population cohort studies based in 
Scotland 
29
. The three original studies took place between 1964 and 1976. Twenty years later, 
in 1996, the next generation was studied when offspring of couples in the original Renfrew/ 
Paisley Study were recruited into the Family Study. This latter group is the subject of the 
present analysis. Details of the study have been described previously 
30
. All 2,120 participants 
used in the current project are of European ancestry and have data on rs1051730 genotype, 
smoking habits, age, sex, asthma and hay fever. 
 
Genotyping 
Genotyping was performed on an ABI PRISM 7900HT sequence detection system using a 
Taqman assay (Assay ID: C_9510307_20, Applied Biosystems), followed by allelic 
discrimination using software from Applied Biosystems (SDS V2.0).3.  
 
Hay fever, asthma, and allergic sensitization 
Classification of participant hay fever was done by the following question: “Do you suffer 
from, or have you ever suffered from hay fever? (Yes/No)”. Participants were classified as 
having asthma if they answered “Yes” to the question: “Do you suffer from, or have you ever 
suffered from asthma?” as well as “Yes” to at least one of the following two questions: “Have 
you suffered from an asthma attack in the last 12 months?” and “Are you currently taking 
medication (puffers or inhalers) for asthma?” Allergic sensitization was not determined. 
 
Smoking status 
The participants completed a questionnaire which included questions on smoking habit. 
Three categories of smoking habit were defined: never smoker, current smoker, and former 
smoker. 
 
Ethics 
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Ethics approval was obtained from the Argyll and Clyde Health Board Local Research Ethics 
Committee.  
 
Funding 
The MIDSPAN Family Study was funded by The Wellcome Trust, and the NHS Research and 
Development Cardiovascular Research Programme. Participants gave their informed consent. 
 
Additional information 
The analyses are not adjusted for principal component. Data on the rs1051730 SNP have 
previously been published 
31-35
. 
  
 
The NEO study 
 
The NEO study was designed for extensive phenotyping to investigate pathways that lead to 
obesity-related diseases 
36
. The NEO study is a population-based, prospective cohort study 
that includes 6,671 individuals aged 45–65 years, with an oversampling of individuals with 
overweight or obesity (BMI > 27 kg/m
2
). At baseline, information on demography, lifestyle, 
and medical history has been collected by questionnaires. In addition, samples of 24-h urine, 
fasting and postprandial blood plasma and serum, and DNA were collected. Participants 
underwent an extensive physical examination, including anthropometry, electrocardiography, 
spirometry, and measurement of the carotid artery intima-media thickness by 
ultrasonography. In random subsamples of participants, magnetic resonance imaging of 
abdominal fat, pulse wave velocity of the aorta, heart, and brain, magnetic resonance 
spectroscopy of the liver, indirect calorimetry, dual energy X-ray absorptiometry, or 
accelerometry measurements were performed. The collection of data started in September 
2008 and completed at the end of September 2012. Participants are currently being followed 
for the incidence of obesity-related diseases and mortality.  
 
Genotyping 
Genotyping was performed using the Illumina HumanCoreExome chip, which was 
subsequently imputed to the 1000 genome reference panal. Genotyping calling algorithm is 
GenCall. Genotyping and SNP call rates >98%. 
 
Hay fever, asthma, and allergic sensitization 
Participants were defined as having asthma if they had the general practitioner record code 
R96 (asthma) according to the International Classification of Primary Care. Hay fever and 
allergic sensitization were not determined. 
 
Smoking status 
Questionnaires on health and lifestyle factors were sent to all participants. Smoking status 
was classified as never-smoker, former smoker, or current smoker on the basis of a 
questionnaire, in which the participants could answer the question “Do you smoke?” as 
either: “No, I never smoked”; “No, but I did smoke in the past”; or “Yes, currently”. Long-
term tobacco exposure was expressed in pack years of smoking, calculated by multiplying the 
number of packs of cigarettes smoked per day by the number of years the participant smoked. 
 
Ethics 
The Medical Ethical Committee of the Leiden University Medical Center (LUMC) approved 
the design of the study. All participants gave their written informed consent. 
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Funding and acknowledgements 
The authors of the NEO study thank all individuals who participated in the Netherlands 
Epidemiology in Obesity study, all participating general practitioners for inviting eligible 
participants and all research nurses for collection of the data. We thank the NEO study group, 
Pat van Beelen, Petra Noordijk and Ingeborg de Jonge for the coordination, lab and data 
management of the NEO study. The genotyping in the NEO study was supported by the 
Centre National de Génotypage (Paris, France), headed by Jean-Francois Deleuze. The NEO 
study is supported by the participating Departments, the Division and the Board of Directors 
of the Leiden University Medical Center, and by the Leiden University, Research Profile 
Area Vascular and Regenerative Medicine. Dennis Mook-Kanamori is supported by Dutch 
Science Organization (ZonMW-VENI Grant 916.14.023).  
 
Additional information 
The analyses are adjusted for principal components (4). The data has not been published 
previously. 
 
 
NSHD 
 
The Medical Research Council National Survey of Health and Development (NSHD) is an 
on-going prospective population based birth cohort study consisting of all births in England, 
Scotland and Wales in one week in March 1946 
37
. The sample includes single births to 
married mothers whose fathers were in non-manual or agricultural occupations and a 
randomly selected one in four of all others, whose fathers were in manual labor. The original 
cohort, now 70 years of age, comprised 2,547 women and 2,815 men who have been 
followed-up over 20 times since their birth. The data collected to date include repeat 
cognitive function, physical, lifestyle and anthropomorphic measures, as well as blood 
analytes and other measures. In 2006-10 the cohort carried out a particularly intensive phase 
of clinical assessment and biological sampling with blood and urine sampling and analysis, 
and cardiac and vascular imaging 
38
.  
 
Genotyping 
DNA was extracted from blood samples collected in 1999 
39
. Genotyping of rs16969968 was 
carried out by LGC Genomics (Hoddesdon, UK; www.lgcgenomics.com) using fluorescence-
based competitive allele-specific PCR (KASPar). Call rate was >95%. 
 
Hay fever, asthma, and allergic sensitization 
The study has data on self-reported hay fever and self-reported asthma. The outcome hay 
fever variable was derived from responses to questions about hay fever asked by research 
nurses at home visits in 1989 (age 43) and 1999 (age 53). In 1989, cohort members were 
asked whether they had ever had hay fever, and in 1999 they were asked whether they had 
had it in the last 10 years. The asthma variable was derived from responses to questions about 
asthma asked by the research nurses at home visits in 1989 and 1999. In 1989, cohort 
members were asked whether they had ever had asthma, and in 1999 they were asked 
whether they had had it in the last 10 years. Allergic sensitization was not determined. 
 
Smoking status 
Smoking status was collected during a home interview in 1999 at age 53 years by trained 
interviewers 
40
. Current cigarette smoking status (“yes”, “no”) and the number of cigarettes 
24 
 
smoked per day was obtained. Study members who provided an affirmative response to being 
current cigarette smokers, regardless of the quantity of cigarettes smoked per day, were 
classified as “smokers”, while those who provided a negative response were classified as 
“non-smoker”. Pipe and cigar smokers who did not also report cigarette smoking were 
excluded from analyses. In the current analyses, we included 2,484 participants with 
rs16969968 genotype, allergic respiratory disease and smoking data available. 
 
Additional information 
The analyses are not adjusted for principal component. Some of the observational or genetic 
data have previously been published in CARTA papers or elsewhere 
41
. 
 
Ethics 
Ethical approval was given by the Central Manchester Research Ethics Committee, and the 
participants gave informed written consent. 
  
Funding and acknowledgements 
We are very grateful to the members of this birth cohort for their continuing interest and 
participation in the study. We would like to acknowledge the Swallow group at University 
College London, who performed the DNA extractions. This work was funded by the Medical 
Research Council [MC_UU_12019/1]. 
 
 
The 1936 Cohort 
 
The 1936 Cohort is a longitudinal population-based study based on a random sample of 1,200 
persons living in 1976 (aged 40 years at the time of the study) and living in 4 municipalities 
(Broendby, Glostrup, Herlev, and Ledoeje-Smoerum) of Copenhagen drawn from the Danish 
Civil Registration. They were invited by a letter for a health examination that focused on risk 
factors for cardiovascular disease. Enclosed was a questionnaire regarding medical history 
and health and lifestyle to be completed in advance. Between 1976 and 1977, a total of 1,052 
participants were examined (participation rate=87·7%). In 1995–1996 all participants were 
invited for a re-examination where a total of 695 were examined (participation rate=66%). 
We use these re-examination data in the current study. 
 
Genotyping 
DNA was extracted and purified from leukocytes (LGC Genomics, Hoddlesdon, UK). All 
participants were genotyped with the Illumina Infinium HumanCoreExome-12 BeadChip 
(CoreExomeChip) using HiScan system (Illumina) at the Novo Nordisk Foundation Centre 
for Basic Metabolic Research, University of Copenhagen, Copenhagen, Denmark. The 
standard pipeline in Illumina Genome Studio software was used for the genotype calling.  
A total of 538,448 markers on 684 individuals entered the Quality Control (QC) pipeline, 
where 9886 markers were removed due to a call-rate below 95% before QC on individuals 
could begin. 28 individuals were excluded due to: 1) a call-rate below 95%, 2) extreme 
positive or negative inbreeding coefficients 3) ethnic outliers using Principal Component 
Analysis (PCA) on ancestral markers, 4) unknown pedigree relation found by Identical By 
Descent (IBD) analysis, where the individual with the lowest call rate for each pedigree-pair 
was removed, 5) sample duplicates, and finally 6) sex discrepancy.  
We used a combination of scripts written in Python (v2.7.3) and R (v3.0.1) 
together with the PLINK (v1.07) software in our QC pipeline. After QC, 656 individuals with 
528,562 markers were ready for imputation. 
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Additional genotypes were imputed with 1,000 Genomes haplotypes Phase I 
integrated variant set release (SHAPE2) in NCBI build 37 (hg19) coordinates, using 
IMPUTE2 
42
 on all markers that passed a Hardy-Weinberg Equilibrium (HWE) filter 
(pHWE<0·005), into the 1000 genomes phase 1 panel 
43
. 
 
Hay fever, asthma, and allergic sensitization 
The questionnaire used in 1995–1996 (at 60 years of age) included the following questions on 
atopic diseases: “Has a doctor ever told you that you had hay fever?” (self-reported hay fever 
if they answered “yes”)” and “Has a doctor ever told you that you had asthma?” (self-
reported asthma if they answered “yes”).  
Measurement of aeroallergen sensitization was performed using the ADVIA 
Centaur® Allergy Screen assay (Bayer HealthCare Diagnostics division, Tarrytown, N.Y., 
USA) that is a multi-allergen assay for the qualitative detection of specific serum IgE 
antibodies specific to common inhalant allergens in serum. The test includes a total of 19 
common inhalant allergens. Allergic sensitization was defined as a positive result of the 
dichotomized assay output.  
 
Smoking status 
Smoking status assessed at the re-examination in 1995-1996 was classified as ”never 
smokers”, “former smokers”, and “current smokers” according to the answers to the 
questions “Do you smoke?” and “”If you don’t smoke now, have you smoked before?”. 
Smoking heaviness was calculated as the sum of self-reported cigarettes with and without 
filter. In the current analyses, we included 557 participants with rs1051730 genotype, allergic 
respiratory disease, and smoking data available.  
 
Ethics 
The study was conducted according to the principles of the Declaration of Helsinki. It was 
approved by the Local Ethics Committee, and participants gave written informed consent. 
 
Additional information 
The analyses are not adjusted for principal component. The current associations have not 
been previously published. 
 
 
UK Biobank 
 
The UK Biobank is a large prospective study with over 500,000 participants from across the 
United Kingdom and aged 40–69 years at recruitment in 2006–2010 44. The study has both 
data from questionnaires, physical measures, sample assays, accelerometry, multimodal 
imaging, genome-wide genotyping and longitudinal follow-up for a large number of health-
related outcomes. In the current study, we use the interim UK Biobank genetic data that 
comprise more than 150,000 samples. We have restricted the analyses to individuals 
genetically defined as Caucasian and to participants that are unrelated. 
 In additional analyses, we excluded the approximately one third of the 
participants who participated in the UK BiLEVE Study because they were selected according 
to smoking habits and lung function 
45
.  
 
Genotyping 
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Approximately 450,000 of the participants have been/are being genotyped using the UK 
Biobank Axiom array from Affymetrix. There are approximately 800,000 markers on this 
array. The other approximately 50,000 samples were genotyped on the closely related UK 
BiLEVE array. These are two very similar arrays with more than 95% common marker 
content.  
 The rs16969968 SNP was directly genotyped and did not demonstrate evidence 
for deviation from Hardy Weinberg Equilibrium. The analysis sample was restricted to 
unrelated individuals, based on a threshold of 0·05 estimated from genetic kinships, and to 
individuals of Caucasian genetic ancestry using principal components analyses (PCA). 
 
Hay fever, asthma, and allergic sensitization 
Hay fever was defined as a positive answer to the question: ”Has a doctor ever told you that 
you have had any of the following conditions? Hayfever, allergic rhinitis, or eczema”. 
Asthma was defined as a positive answer to the question: “Has a doctor ever told you that 
you have had any of the following conditions? Asthma” Of note, the data includes 
information about age at first diagnosis which enabled us to exclude participants below 16 
years at diagnosis in additional analyses. Allergic sensitization was not determined. 
 
Smoking status 
Participants were asked about current and past tobacco (cigarette, pipe, cigar or other) 
smoking behavior in a computerized questionnaire.  A full list of the questions is available at: 
http://biobank.ctsu.ox.ac.uk/crystal/docs/TouchscreenQuestionsMainFinal.pdf.  Two 
questions were asked about current and past smoking status: “Do you smoke tobacco now?” 
(Yes, on most or all days, Only occasionally, No, Prefer not to answer) and “In the past, how 
often have you smoked tobacco?” (Smoked on most or all days, Smoked occasionally, Just 
tried once or twice, I have never smoked, Prefer not to answer). From the answers to these 
two questions, individuals were categorized as current (current daily or occasional smokers), 
former (past daily or occasional smokers) or never smokers (individuals who had never tried 
tobacco or had smoked tobacco once or twice). 
 
Additional information 
The analyses are adjusted for 15 principal components. The allergy- and smoking-associated 
SNP associations have not been previously published. 
 
Ethics 
Each participant has given informed consent. An independent Ethics and Governance Council 
oversees adherence to the Ethics and Governance Framework 
44
. 
  
Funding and acknowledgements 
UK Biobank has received funding from the UK Medical Research Council, Wellcome Trust, 
Department of Health, British Heart Foundation, Diabetes UK, Northwest Regional 
Development Agency, Scottish Government, and Welsh Assembly Government. As 
described in the manuscript, the MRC and Wellcome Trust played a key role in the decision 
to establish UK Biobank, a large, population-based, prospective, open access resource that 
would allow detailed investigations of the genetic and environmental determinants of the 
diseases of middle and old age. The MRC, Wellcome Trust, Department of Health, and 
Scottish Chief Scientist Office each have a representative on the UK Biobank Board. The 
MRC and Wellcome Trust fund the independent Ethics and Governance Council 
44
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Whitehall II 
Whitehall II is a cohort study with recruitment of 10,308 participants (70% men) between 
1985 and 1988 involved 20 London based Civil service departments [83]. Genetic samples 
were collected in 2004 from over 6,000 participants. The study is highly phenotyped for 
cardiovascular and other ageing related health outcomes, with 9 phases of follow up (5 with 
clinical assessment and biological sampling), over 20 years of follow up. A wide variety of 
health behaviour and environmental data are also collected and the participants are consented 
for linkage to recorded clinical data such as Hospital Episode Statistics (HES), the Office of 
National Statistics mortality data and the national registry of acute coronary syndromes in 
England and Wales (Myocardial Ischaemia National Audit Project). 
 
Genotyping 
Genotyping of rs16969968 was performed as part of genotyping using the Metabochip 
46
 
 
Hay fever, asthma, and allergic sensitization 
Hay fever and asthma were measured at phase 1. Hay fever was defined as a positive answer 
to the question: “There are some kinds of health problems that keep recurring and some that 
people have all the time. In the last 12 months have you suffered from any of the following 
health problems? Hay fever” Asthma was defined as a positive answer to the question: 
“There are some kinds of health problems that keep recurring and some that people have all 
the time. In the last 12 months have you suffered from any of the following health problems? 
Asthma” Allergic sensitization was not determined. 
 
Smoking status 
Information on smoking status was collected by questionnaire during the first phase of data 
collection. Individuals who reported smoking cigars or pipes but not cigarettes were excluded 
from all analyses. 
 
Additional information 
The analyses are not adjusted for principal components.  
 
Ethics 
Ethical approval for the Whitehall II study was obtained from the University College London 
Medical School committee on the ethics of human research. Informed consent was gained 
from every participant. 
  
Funding and acknowledgements 
The Whitehall II study has been supported by grants from the Medical Research Council 
(K013351); British Heart Foundation; Health and Safety Executive; Department of Health; 
National Heart Lung and Blood Institute (NHLBI: HL36310) and National Institute on Aging 
(AG13196), US, NIH; Agency for Health Care Policy Research (HS06516); and the John D 
and Catherine T MacArthur Foundation Research Networks on Successful Midlife 
Development and Socio-economic Status and Health.  
 
SHIP 
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The Study of Health in Pomerania (SHIP) is a population-based cohort study in the German 
region of West Pomerania. SHIP was at first planned as a cross-sectional study  
47
. 
Examinations were performed in centers located at Stralsund and Greifswald between the 
16th of October 1997 and the 19th of May 2001. SHIP-0 had a response of 68·8%. The 
response in women was slightly higher (69·4%) than in men (68·2%). Participation in the 
different age groups for women ranged from 76·6% (participants aged between 50 and 60) to 
49·5% (participants aged between 70 and 80) and for men from 74·3% (participants aged 
between 50 and 60) to 63·2% (participants aged between 70 and 80) 
48
.  
  
Genotyping 
Genotyping was performed using the Human SNP 6.0 Array (Affymetrix, Santa Clara, CA, 
USA). Hybridization of genomic DNA was genotyped according to the manufacturer’s 
standard recommendations. Genotypes were determined using the Birdseed2 clustering 
algorithm. All remaining arrays had a sample call rate > 92 %.  
 
Hay fever, asthma, and allergic sensitization 
Participants were classified as having hay fever if they answered confirmatory to the 
question: “Do you sometimes or all the time suffer from hay fever?” The participants were 
defined as having allergic asthma or not according to self-reported questionnaire information. 
Allergic sensitization was not determined. 
 
Smoking status 
The participants completed an interview-based questionnaire which included questions on 
smoking habit. Three categories of smoking habits were defined: never, former and current 
smokers. 
 
Additional information 
The analyses are not adjusted for principal components.  
 
Ethics 
SHIP was planned and accompanied with support and advice from an external Data Safety 
and Monitoring Committee (DSMC). Each participant gave written informed consent. The 
study conformed to the principles of the Declaration of Helsinki and was approved by the 
Ethics Committee of the University of Greifswald. 
  
Funding and acknowledgements 
The Study of Health in Pomerania (SHIP) is part of the Research Network of Community 
Medicine (www.community-medicine.de). 
 
SHIP TREND 
 
SHIP-TREND is the second cohort of the population project Study of Health in Pomerania 
(SHIP). Baseline data were collected between 2008 and 2012 
48
.  
 
Genotyping 
Genotyping was performed using the Human SNP 6.0 Array (Affymetrix, Santa Clara, CA, 
USA). Hybridization of genomic DNA was genotyped according to the manufacturer’s 
standard recommendations. Genotypes were determined using the Birdseed2 clustering 
algorithm. All remaining arrays had a sample call rate > 92 %.  
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Hay fever, asthma, and allergic sensitization 
In the standardized interview, participants were asked whether a physician had ever 
diagnosed them with allergy, and if so, which type of allergy. Participants who answered 
“allergy to house dust mite” or “pollen allergy” were defined as having hay fever in the 
current study. A diagnosis of lung asthma was defined as the participants that reported to 
have bronchial asthma. Allergic sensitization was not determined. 
 
Smoking status 
The participants completed an interview-based questionnaire which included questions on 
smoking habit. Three categories of smoking habits were defined: never, former and current 
smokers. 
 
Additional information 
The analyses are not adjusted for principal components. 
 
Ethics 
SHIP was planned and accompanied with support and advice from an external Data safety 
and Monitoring Committee (DSMC). Each participant gave written informed consent. The 
study conformed to the principles of the Declaration of Helsinki and was approved by the 
Ethics Committee of the University of Greifswald. 
  
Funding and acknowledgements 
The Study of Health in Pomerania (SHIP) is part of the Research Network of Community 
Medicine (www.community-medicine.de). 
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Main supplementary tables 
 
Table S1. Descriptive statistics of study populations. 
    
      
Hay fever Asthma 
Allergic 
sensitization 
  
Smoking 
status 
Smoking 
heaviness 
N 
% 
Male 
Median age 
(IQR) 
N % N % N % 
1958 BC Never  2,308 50·6 42 (42, 42) 535 23·2  186 8·1 473  20·5 
  Former  1,400 51·9 42 (42, 42) 264 18·9  123 8·8  233 16·6  
  Current X 1,174 47·3 42 (42, 42) 168 14·3  97 8·3 161 13·7 
  Total  4,882 50·1 42 (42, 42) 967 19·8 406 8·3 867  17·8 
ALSPAC Children  Never  1,275 39·8 18·6 (18·2,19) 532  41·7  283 22·2 NA  NA 
  Current X 274 32·1 18·7 (18·2,19·1)  133 48·5 77 28·1  NA NA 
  Total  1,549 38·4 18·6 (18·2,19) 665  42·9  360 23·2 NA NA 
ALSPAC Mothers Never  2,715 0 37·2 (35·1,40·1)  1,068 39,3  433 16·0 NA   NA 
  Former  1,238 0 38·1 (35·1,41·1)  478 38,6  198 16·0  NA  NA 
  Current X 881 0 35·3 (32·2,39·1)  298 33,8  160 18·2  NA  NA 
  Total  4,834 0 37·1 (34·2,40·1) 1,844 38,1 791 16·4  NA NA 
COPSAC2000 Never  412 43·0 33·1 (29·6, 36·5) 237  57·5  262 63·6  217 52·7  
  Current  131 53·4 32·4 (28·9, 36·9) 56  42·8  73 55·8 56 42·8 
  Total  543 45·5 33·0 (29·3, 36·6)  293 54·0  335 61·7  273 50·3  
Dan-Monica10 Never  614 36·8 51·8 (42·1, 61·7) 80  13·0  31 5·1 115  18·7  
  Former  514 63·4 61·4 (51·3, 71·2)  65 12·6 48 9·3  89 17·3  
  Current X 926 46·9    51·8 (41·9, 61·6) 88  9·5  63 6·8  172 18·6  
  Total  2,054 48·0 52·0 (42·0, 61·8)  233 11·3 142 6·9 376 18·3 
ELSA Never  1,816 33·3 62 (55, 70) NA NA 200 11·0 NA NA 
 Former  2,606 54·6 64 (56, 72) NA NA 326 12·5 NA NA 
 Current X 841 45·1 59 (54, 66) NA NA 88 10·5 NA NA 
 Total  5,263 45·7 62 (55, 70) NA NA 614 11·7 NA NA 
FINRISK* Never  13,631 35·3 49 (37,59) NA  NA 653 4·8 NA  NA  
  Former  5,308 60·9 53 (42, 62)  NA  NA 286 5·4 NA  NA  
  Current X 6,424 57·1 44 (34,53)  NA NA  227 3·5 NA  NA  
  Total  25,363 46·2 48 (37,59)  NA NA  1,166 4·6 NA  NA  
FINRISK** Never  9,909 36·1 50 (38,61) 1,550 15·6 NA  NA NA  NA 
  Former  4,106 61·0 54 (44, 63) 596 14·5   NA  NA  NA  NA 
  Current X 4,567 57·5 45 (35,54) 633 13·9   NA NA   NA NA  
  Total  18,582 46·9 49 (38,60) 2,779 15·0   NA NA   NA NA  
GOYA Females*** Never  1,492 0 29·7 (27·1, 32·6) 272  19·5  131 8·8  NA  NA 
  Current  524 0 28·5 (25·6, 32·0) 68  13·6 51 9·8  NA NA  
  Total  2,016 0 29·5 (26·7, 32·5) 340  17·9  182 9·1  NA NA  
GOYA Males Never  178 100 44 (40, 49) 35 19·7 12 6·7 NA NA 
 Former  217 100 48 (42, 54) 24 11·1 7 3·2 NA NA 
 Current X 394 100 47 (42, 55) 42 10·7 16 4·1 NA NA 
 Total  789 100 46 (41, 53) 101 12·8 35 4·4 NA NA 
Health2006 Never  1,363 44·5 48 (38, 60)  280 20·5  138 10·1 375 27·5  
  Former  1,063 45·7 53 (44, 61) 192  18·1 134 12·6 215 20·2 
31 
 
  Current X 717 40·2 50 (41, 58)  99 13·8 70 9·8 140 19·5 
  Total  3,143 43·9 50 (41, 60) 571 18·2  342 10·9  730 23·2 
Health2008 Never  279 47·7 44·0 (38·2,51·8) 76 27·2 37 13·3 93 33·3 
  Former  218 39·9 50·1 (42·9, 55·1) 37  17·0 18 8·3  53 24·3 
  Current X 121 45·4 48·0 (40·6, 54·5)  16 13·2 17 14·5 20  16·5 
  Total  618 44·5 46·8 (40·6, 53·6)  129 20·9 72 11·6 166 26·9 
HUNT2 Never  19,353   39·5 47 (33,64) 3,903  20·2 1,451 7·5 NA  NA   
  Former  11,241    57·4 53 (42,67) 2,175  19·4 1,078 9·6 NA   NA   
  Current X 12,617   44·3 46 (36,57) 2,146  17·0 1,109 8·8 NA   NA   
  Total  43,211   45·6 48 (36,63) 8,224  19·0 3,638 8·4 NA   NA   
Inter99 Never  1,825 45·6 45·0(39·9,50·2) NA  NA  176 9·6 690 37·8 
  Former  1,347 50·8 49·7(40·1,54·8) NA  NA  112 8·3 427 31·7 
  Current X 1,819 49·2 45·1 (40·0, 50·2) NA  NA  151 8·3  565 31·1  
  Total  4,991 48·3 45·1 (40·0, 50·3) NA  NA  439 8·8 1,682 33·7 
KORA Never  369 39·6 45 (28, 76) 84 22·8 21 5·7 176 47·8 
 Former  259 54·1 46 (29, 73) 56 21·6 19 7·3 123 47·5 
 Current X 209 54·6 41 (29, 60) 32 15·3 13 6·2 103 49·6 
 Total  837 47·8 44 (28, 76) 172 20·6 53 6·3 402 48·1 
MIDSPAN Never  1003 42·6 44 (40, 49) 240 23·9 50 5·0 NA NA 
 Former  578 49·3 47 (42, 50) 116 20·1 30 5·2 NA NA 
 Current X 539 44·0 45 (40, 49·5) 86 16·0 23 4·3 NA NA 
 Total  2120 44·8 45 (41, 49) 442 20·8 103 4·9 NA NA 
NEO Never  1892 42·9 56 (50, 61) NA NA 211 11·2 NA NA 
 Former  2778 49·1 57 (53, 62) NA NA 315 11·3 NA NA 
 Current X 831 57·3 55 (50, 60) NA NA 61 7·3 NA NA 
 Total  5501 48·2 57 (51, 61) NA NA 587 10·7 NA NA 
NSHD Never  733 42·7 53 (53, 53) 194  26·5 83 11·3 NA  NA  
  Former  1,186 53·4 53 (53, 53)  283 23·9 116 9·8  NA NA  
  Current X 565 49·2 53 (53, 53) 118 20·9 52 9·2  NA NA  
  Total  2,484 49·3 53 (53, 53) 595 23·9 251 10·1  NA NA  
The 1936 Cohort Never  201 34·3 60·5 (60·2, 60·8) 20 10·0 18 9·0 26 12·9 
 Former  154 62·3 60·5 (60·2, 60·8) 20 13·0 8 5·2 27 17·5 
 Current X 202 50·5 60·5 (60·2, 60·8) 9 4·5 14 6·9 24 11·9 
 Total  557 47·9 60·5 (60·2, 60·8) 49 8·8 40 7·2 77 13·8 
UK Biobank Never  61,315 43·6 57 (50, 63) 15,268 24·9 7,726 12·6 NA NA 
 Former  38,296 50·6 60 (53, 64) 8,075 21·1 4,801 12·5 NA NA 
 Current X 13,344 49·0 55 (48, 61) 2,320 17·4 1·521 11·4 NA NA 
 Total  112,955 49·0 58 (51, 63) 25,663 22·7 14,048 12·4 NA NA 
Whitehall II Never  1,218 71·9 43 (39, 49) 242 19·9 45 3·7 NA NA 
 Former  730 79·2 44 (40, 49) 133 18·2 31 4·3 NA NA 
 Current X 351 72·9 43 (39, 49) 46 13·1 10 2·9 NA NA 
 Total  2,299 74·4 43 (39, 49) 421 18·3 86 3·7 NA NA 
SHIP Never  1,428 29·0 54 (39, 64) 134 9·4 157 11·0 NA NA 
 Former  1,374 65·4 56 (42, 68) 110 8·0 181 13·2 NA NA 
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 Current  1,225 54·5 40 (31, 51) 76 6·2 130 10·6 NA NA 
 Total  4,027 49·1 50 (36, 63) 320 8·0 468 11·6 NA NA 
SHIP TREND Never  419 32·7 53 (41, 63) 55 13·1 17 4·1 NA NA 
 Former  351 56·1 53 (44, 63) 55 15·7 13 3·7 NA NA 
 Current  214 45·3 43 (34, 51) 31 14·5 11 5·1 NA NA 
 Total  984 43·8 50 (40, 61) 141 14·3 41 4·2 NA NA 
*For asthma. ** For hay fever. 
***
 A total of 2,016 women had information on asthma or hay fever, whereas only 
2,009 and 1,897, respectively, had information on asthma and hay fever. 
Abbreviations: 1958 BC, British 1958 Birth Cohort; ALSPAC, Avon Longitudinal Survey of Parents and 
Children; COPSAC2000, Copenhagen Prospective study on Asthma in Childhood; ELSA, English Longitudinal 
Study of Ageing; FINRISK, Finland Cardiovascular Risk Study; GOYA, Genomics of extremely Overweight in 
Young Adults; HUNT, Nord-Trøndelag Health Study; Inter99, Intervention 1999; IQR, interquartile range; 
KORA, Cooperative Health Research in the Region of Augsburg; MIDSPAN, the Middle-aged Span-of-Life; 
Monica, Monitoring of trends and determinants in Cardiovascular Diseases; NA, not available; NEO, 
Netherlands Epidemiology of Obesity; NSHD, National Survey of Health and Development; SHIP, Study of 
Health in Pomerania; UK Biobank, United Kingdom Biobank. 
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Table S2. Allele frequencies for rs1051730/rs16969968 in the CARTA studies 
Study SNP Major homozygotes Heterozygotes Minor homozygotes MAF HW, p-value Total 
1958 BC rs16969968 2,191 2,167 596 0·34 0·25 4,882 
ALSPAC Children  rs1051730 675 705 169 0·34 0·45 1,549 
ALSPAC Mothers rs1051730 2,160 2,144 530 0·33 0·95 4,834 
COPSAC2000 rs1051730 243 240 60 0·33 0·95 543 
Dan-Monica10 rs1051730 915 900 239 0·34 0·61 2,054 
ELSA rs16969968 2,400 2,296 567 0·33 0·61 5,263 
FINRISK* rs16969968 11,527 11,159 2,677 0·33 0·76 25,363 
GOYA Females rs1051730 217 902 897 0·33 0·66 2,016 
GOYA Males rs1051730 348 340 101 0·34 0·21 789 
Health2006 rs1051730 1,411 1,394 338 0·33 0·82 3,143 
Health2008 rs16969968 287 268 63 0·32 0·97 618 
HUNT2 rs1051730 19,294 19,039 4,878 0·33 0·080 43,211 
Inter99 rs1051730 2,195 2,242 554 0·34 0·61 4,991 
KORA rs1051730 321 416 100 0·37 0·053 837 
MIDSPAN rs1051730 964 939 217 0·32 0·58 2,120 
NEO Rs1051730 2,588 2,385 528 0·31 0·82 5,501 
NSHD rs16969968 1,160 1,081 243 0·32 0·70 2,484 
The 1936 Cohort rs1051730 243 262 52 0·33 0·12 557 
UK Biobank rs1051730 49,911 50,524 12,520 0·33 0·12 112,955 
Whitehall II rs16969968 1,063 1,008 233 0·32 0·79 2,304 
SHIP rs16969968 1,743 1,784 500 0·35 0·19 4,027 
SHIP TREND rs16969968 452 419 113 0·33 0·30 984 
*
 For asthma. The study population for hay fever is smaller, please see Table S1. 
Abbreviations: 1958 BC, British 1958 Birth Cohort; ALSPAC, Avon Longitudinal Survey of Parents and Children; COPSAC2000, Copenhagen Prospective study on Asthma 
in Childhood; ELSA, English Longitudinal Study of Ageing; FINRISK, Finland Cardiovascular Risk Study; GOYA, Genomics of extremely Overweight in Young Adults; 
HW, Hardy Weinberg Equilibrium; HUNT, Nord-Trøndelag Health Study; Inter99, Intervention 1999; KORA, Cooperative Health Research in the Region of Augsburg; 
MIDSPAN, the Middle-aged Span-of-Life; MAF, minor allele frequency, Monica, Monitoring of trends and determinants in Cardiovascular Diseases; NEO, Netherlands 
Epidemiology of Obesity; NSHD, National Survey of Health and Development; SHIP, Study of Health in Pomerania; UK Biobank, United Kingdom Biobank. 
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Table S3.  
Study-specific measures of hay fever, asthma and allergic sensitization.
  
Study Hay fever Asthma Allergic sensitisation 
1958 BC A positive answer to the 
question: “Have you ever 
had hay fever?” 
A positive answer to the 
question: “Have you ever 
had hay asthma?” 
Serum specific IgE 
positivity against inhalant 
allergens 
ALSPAC Children A positive answer to the 
question: “Have you ever 
had hay fever?” 
A positive answer to the 
question: “Have you ever 
had asthma?” 
NA 
ALSPAC Mothers Answering  ”Yes- had it 
recently (in the past year)” 
or ”Yes, in the past, not 
recently” to the question: ” 
Have you ever had any of 
the following problems: 
hay fever?” 
Answering  ”Yes- had it 
recently (in the past year)” 
or ”Yes, in the past, not 
recently” to the question: ” 
Have you ever had any of 
the following problems: 
asthma?” 
NA 
COPSAC2000 Doctor-diagnosed hay 
fever or a positive answer 
to the question: “Have you 
ever had hay fever?” 
Doctor-diagnosed asthma  
Serum specific IgE 
positivity against inhalant 
allergens 
Dan-Monica10 A positive answer to the 
question: “Has a doctor 
ever told you that you had 
allergic hay fever?” 
A positive answer to the 
question: “Has a doctor 
ever told you that you had 
asthma?” 
Serum specific IgE 
positivity against inhalant 
allergens 
ELSA 
NA 
A positive answer to the 
question: “Has a doctor 
ever told you that you 
have/have had any of the 
following conditions 
(asthma)?” 
NA 
FINRISK Answering last week, last 
month or last year to the 
question: “When have you 
last used hay fever 
medication” 
A positive answer to the 
question: “Has a doctor 
ever told you that you had 
asthma?” 
NA 
GOYA Females A positive answer to the 
question: “Has a doctor 
ever told you that you had 
allergic rhinitis?” 
A positive answer to the 
question: “Has a doctor 
ever told you that you had 
asthma?” 
NA 
GOYA Males A positive answer to the 
question: “Does food, 
medicine or grass give you 
hay fever” 
A positive answer to the 
question: “Does food, 
medicine, or grass give you 
asthma?” 
NA 
Health2006 A positive answer to the 
question: “Has a doctor 
ever told you that you had 
hay fever?” 
A positive answer to the 
question: “Has a doctor 
ever told you that you had 
asthma?” 
Serum specific IgE 
positivity against inhalant 
allergens 
Health2008 A positive answer to the 
question: “Has a doctor 
ever told you that you had 
hay fever?” 
A positive answer to the 
question: “Has a doctor 
ever told you that you had 
asthma?” 
Serum specific IgE 
positivity against inhalant 
allergens 
HUNT2 A positive answer to the 
question: “Do you have 
hay fever or nasal 
allergies?” 
A positive answer to the 
question: “Do you have or 
have you had asthma?” 
NA 
Inter99 
NA 
A positive answer to the 
question: “Has a doctor 
ever told you that you had 
asthma?” 
Serum specific IgE 
positivity against inhalant 
allergens 
KORA A positive answer to the 
question: “Has a doctor 
A positive answer to the 
question: “Has a doctor 
Serum specific IgE 
positivity against inhalant 
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ever told you that you had 
hay fever?” 
ever told you that you had 
asthma?” 
allergens 
MIDSPAN 
A positive answer to the 
question: “Do you suffer 
from, or have you ever 
suffered from hay fever?” 
A positive answer to the 
question: “Do you suffer 
from, or have you ever 
suffered from asthma?” and 
a positive answer to at least 
one of the following two 
questions: “Have you 
suffered from an asthma 
attack in the last 12 
months?” and “Are you 
currently taking medication 
(puffers or inhalers) for 
asthma?” 
NA 
NEO 
NA 
Asthma recorded by 
general practitioner  
NA 
NSHD A positive answer to the 
question: “Have you ever 
had hay fever?” or “Have 
you had hay fever in the 
last 10 years?”   
A positive answer to the 
question: “Have you ever 
had asthma?” or “Have you 
had asthma in the last 10 
years?”  
NA 
The 1936 Cohort A positive answer to the 
question: “Has a doctor 
ever told you that you had 
hay fever?” 
A positive answer to the 
question: “Has a doctor 
ever told you that you had 
asthma?” 
Serum specific IgE 
positivity against inhalant 
allergens 
UK Biobank A positive answer to the 
question: ”Has a doctor 
ever told you that you have 
had any of the following 
conditions? Hay fever, 
allergic rhinitis or eczema” 
A positive answer to the 
question: “Has a doctor 
ever told you that you have 
had any of the following 
conditions? Asthma“ 
NA 
Whitehall II A positive answer to: “In 
the last 12 months have 
you suffered from any of 
the following health 
problems? Hay fever” 
A positive answer to: “In 
the last 12 months have 
you suffered from any of 
the following health 
problems? Asthma” 
NA 
SHIP 
A confirmative answer to 
the question: “Do you 
sometimes or all the time 
suffer from hay fever?” 
The participants were 
defined as having allergic 
asthma or not according to 
self-reported questionnaire 
information. 
NA 
SHIP TREND Self-reported doctor-
diagnosed “allergy to house 
dust mite” or “pollen 
allergy” 
Participants who reported 
to have bronchial asthma 
NA 
Abbreviations: 1958 BC, British 1958 Birth Cohort; ALSPAC, The Avon Longitudinal Survey of Parents and Children; 
COPSAC2000, Copenhagen Prospective study on Asthma in Childhood; ELSA, the English Longitudinal Study of 
Ageing; FINRISK, Finland Cardiovascular Risk Study; GOYA, Genomics of extremely Overweight in Young Adults; 
HUNT, Nord-Trøndelag Health Study; IgE, immunoglobulin E; ICPC, International Classification of Primary Care; 
Inter99, Intervention 1999; KORA, The Cooperative Health Research in the Region of Augsburg; MIDSPAN, the 
Middle-aged Span-of-Life; Monica, Monitoring of trends and determinants in Cardiovascular Diseases; NA, not 
available; NEO, Netherlands Epidemiology of Obesity; NSHD, National Survey of Health and Development; SHIP, 
Study of Health in Pomerania; UK Biobank, United Kingdom Biobank. 
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Main supplementary figures 
 
Figure S1-S3 
Age- and sex- adjusted association of smoking status with hay fever, asthma and allergic 
sensitization. 
Current smokers
Health2008
SHIP
The 1936 Cohort
GOYA Males
1958 BC
COPSAC2000
KORA
Whitehall II
UK Biobank
MIDSPAN
Health2006
GOYA Females
Dan-Monica10
NSHD
ALSPAC Mothers
HUNT2
FINRISK
SHIP TREND
ALSPAC Children
I-V Subtotal  (I-squared = 84.3%, p = 0.000)
D+L Subtotal
Former smokers
Health2008
GOYA Males
1958 BC
NSHD
UK Biobank
MIDSPAN
Health2006
SHIP
Whitehall II
ALSPAC Mothers
KORA
HUNT2
Dan-Monica10
FINRISK
SHIP TREND
The 1936 Cohort
I-V Subtotal  (I-squared = 81.3%, p = 0.000)
D+L Subtotal
Study
0.41 (0.23, 0.74)
0.46 (0.34, 0.62)
0.50 (0.22, 1.15)
0.52 (0.32, 0.85)
0.55 (0.46, 0.67)
0.60 (0.38, 0.94)
0.60 (0.38, 0.95)
0.60 (0.43, 0.85)
0.61 (0.58, 0.64)
0.62 (0.47, 0.81)
0.63 (0.49, 0.81)
0.66 (0.49, 0.88)
0.71 (0.51, 0.98)
0.73 (0.56, 0.94)
0.77 (0.66, 0.91)
0.80 (0.75, 0.85)
0.86 (0.77, 0.95)
0.90 (0.55, 1.47)
1.33 (1.02, 1.73)
0.69 (0.67, 0.72)
0.68 (0.61, 0.76)
0.54 (0.35, 0.85)
0.55 (0.31, 0.96)
0.77 (0.65, 0.91)
0.86 (0.69, 1.06)
0.86 (0.84, 0.89)
0.87 (0.68, 1.12)
0.90 (0.73, 1.11)
0.91 (0.69, 1.20)
0.92 (0.73, 1.17)
0.97 (0.85, 1.11)
0.98 (0.66, 1.44)
1.07 (1.01, 1.13)
1.12 (0.78, 1.61)
1.16 (1.04, 1.29)
1.35 (0.89, 2.04)
1.97 (0.98, 3.94)
0.91 (0.89, 0.94)
0.94 (0.86, 1.03)
ratio (95% CI)
Odds
  
1.2 .4 .6 .8 2 3 4
Odds ratio compared to never smokers
Hay fever
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NOTE: Weights are from random effects analysis
.
.
Current smokers
GOYA Males
Whitehall II
NSHD
NEO
Inter99
MIDSPAN
UK Biobank
FINRISK
The 1936 Cohort
Health2006
ELSA
1958 BC
GOYA Females
KORA
COPSAC2000
Health2008
ALSPAC Mothers
SHIP
HUNT2
ALSPAC Children
Dan-Monica10
SHIP TREND
Subtotal  (I-squared = 61.3%, p = 0.000)
Former smokers
GOYA Males
Health2008
The 1936 Cohort
NSHD
Inter99
ALSPAC Mothers
UK Biobank
NEO
SHIP TREND
MIDSPAN
1958 BC
Whitehall II
FINRISK
ELSA
SHIP
HUNT2
KORA
Health2006
Dan-Monica10
Subtotal  (I-squared = 67.2%, p = 0.000)
study
0.57 (0.26, 1.24)
0.76 (0.38, 1.52)
0.80 (0.55, 1.15)
0.84 (0.70, 1.01)
0.86 (0.68, 1.08)
0.86 (0.52, 1.42)
0.88 (0.83, 0.93)
0.92 (0.78, 1.08)
0.92 (0.44, 1.93)
0.97 (0.71, 1.31)
0.98 (0.75, 1.28)
1.02 (0.79, 1.32)
1.05 (0.75, 1.49)
1.08 (0.52, 2.22)
1.08 (0.51, 2.30)
1.09 (0.58, 2.04)
1.11 (0.90, 1.36)
1.14 (0.87, 1.48)
1.19 (1.10, 1.29)
1.36 (1.01, 1.82)
1.42 (0.91, 2.22)
1.45 (0.64, 3.28)
1.00 (0.91, 1.09)
0.45 (0.17, 1.17)
0.59 (0.32, 1.09)
0.78 (0.32, 1.89)
0.86 (0.63, 1.15)
0.86 (0.67, 1.11)
1.01 (0.84, 1.21)
1.03 (0.99, 1.07)
1.03 (0.85, 1.24)
1.08 (0.51, 2.29)
1.08 (0.68, 1.74)
1.10 (0.87, 1.40)
1.17 (0.73, 1.88)
1.18 (1.01, 1.36)
1.25 (1.03, 1.51)
1.25 (0.98, 1.59)
1.30 (1.20, 1.42)
1.34 (0.70, 2.56)
1.39 (1.07, 1.79)
2.01 (1.24, 3.26)
1.11 (1.01, 1.21)
ratio (95% CI)
Odds
  
1.09 .3 2 3
Odds ratio compared to never smokers
Asthma
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Current smokers
Health2008
1958 BC
Health2006
COPSAC2000
Inter99
The 1936 Cohort
Dan-Monica10
KORA
I-V Subtotal  (I-squared = 55.6%, p = 0.027)
D+L Subtotal
Former smokers
Health2008
Health2006
1958 BC
Inter99
Dan-Monica10
KORA
The 1936 Cohort
I-V Subtotal  (I-squared = 16.6%, p = 0.303)
D+L Subtotal
study
0.42 (0.24, 0.72)
0.62 (0.51, 0.76)
0.67 (0.54, 0.84)
0.74 (0.49, 1.11)
0.74 (0.65, 0.85)
0.89 (0.49, 1.62)
0.94 (0.72, 1.23)
1.07 (0.75, 1.51)
0.73 (0.67, 0.80)
0.74 (0.64, 0.86)
0.72 (0.48, 1.08)
0.74 (0.61, 0.90)
0.77 (0.65, 0.92)
0.78 (0.68, 0.91)
0.95 (0.69, 1.30)
1.01 (0.73, 1.39)
1.37 (0.75, 2.49)
0.80 (0.74, 0.88)
0.81 (0.73, 0.90)
ratio (95% CI)
Odds
  
1.2 .4 .6 .8 2 3
Odds ratio compared to never smokers
Allergic sensitization
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Figure S4  
Age- and sex-adjusted association of smoking heaviness with hay fever, asthma and allergic 
sensitization.  
Hay fever
KORA
The 1936 Cohort
Whitehall II
FINRISK
Health2006
1958 BC
GOYA Males
UK Biobank
HUNT2
NSHD
ALSPAC Mothers
ALSPAC Children
Dan-Monica10
MIDSPAN
Health2008
I-V Subtotal  (I-squared = 33.7%, p = 0.099)
D+L Subtotal
Asthma
KORA
MIDSPAN
GOYA Males
The 1936 Cohort
Whitehall II
ALSPAC Children
Inter99
NSHD
FINRISK
NEO
HUNT2
Health2008
1958 BC
UK Biobank
Dan-Monica10
ELSA
ALSPAC Mothers
Health2006
I-V Subtotal  (I-squared = 0.0%, p = 0.482)
D+L Subtotal
Allergic sensitization
Health2006
The 1936 Cohort
1958 BC
Inter99
Dan-Monica10
Health2008
KORA
I-V Subtotal  (I-squared = 23.3%, p = 0.252)
D+L Subtotal
study
207
168
313
4567
717
1174
394
10732
12178
560
877
274
926
926
117
207
926
394
168
226
274
1720
560
6424
831
12178
117
1174
10732
926
669
877
717
717
168
1174
1720
926
117
206
N
0.94 (0.89, 0.99)
0.95 (0.85, 1.06)
0.97 (0.93, 1.00)
0.97 (0.96, 0.98)
0.97 (0.94, 1.00)
0.99 (0.96, 1.01)
0.99 (0.95, 1.02)
0.99 (0.98, 0.99)
0.99 (0.98, 1.00)
0.99 (0.97, 1.02)
1.00 (0.98, 1.02)
1.00 (0.96, 1.04)
1.00 (0.97, 1.03)
1.01 (0.98, 1.03)
1.03 (0.96, 1.11)
0.99 (0.98, 0.99)
0.99 (0.98, 0.99)
0.96 (0.90, 1.03)
0.97 (0.92, 1.03)
0.99 (0.94, 1.04)
0.99 (0.91, 1.09)
1.00 (0.94, 1.07)
1.00 (0.96, 1.05)
1.00 (0.98, 1.02)
1.00 (0.97, 1.03)
1.00 (0.99, 1.02)
1.00 (0.98, 1.03)
1.01 (0.99, 1.02)
1.01 (0.94, 1.08)
1.02 (0.99, 1.04)
1.02 (1.01, 1.02)
1.02 (0.99, 1.06)
1.03 (0.99, 1.06)
1.03 (1.01, 1.05)
1.03 (1.00, 1.06)
1.01 (1.01, 1.02)
1.01 (1.01, 1.02)
0.98 (0.95, 1.00)
0.99 (0.92, 1.06)
0.99 (0.97, 1.01)
1.00 (0.98, 1.01)
1.01 (0.99, 1.03)
1.02 (0.95, 1.10)
1.03 (0.99, 1.06)
1.00 (0.99, 1.01)
1.00 (0.99, 1.01)
ratio (95% CI)
Odds
  
1.85 .9 .95 1.05 1.1
Odds ratio per cigarette per day
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Figure S5-S7 
Mendelian randomisation analysis of the age- and sex-adjusted associations of 
rs1051730/rs16969968 and hay fever, asthma and allergic sensitization. 
 
A B 
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Never smokers
GOYA Males
Whitehall II
NSHD
SHIP
Health2006
1958 BC
MIDSPAN
UK Biobank
The 1936 Cohort
ALSPAC Children
SHIP TREND
COPSAC2000
HUNT2
FINRISK
ALSPAC Mothers
Health2008
GOYA Females
Dan-Monica10
KORA
Subtotal  (I-squared = 16.5%, p = 0.252)
Former smokers
SHIP
SHIP TREND
Health2006
KORA
NSHD
Whitehall II
Dan-Monica10
FINRISK
UK Biobank
1958 BC
ALSPAC Mothers
HUNT2
Health2008
MIDSPAN
GOYA Males
The 1936 Cohort
Subtotal  (I-squared = 0.0%, p = 0.991)
Current smokers
Whitehall II
KORA
SHIP
1958 BC
Health2006
GOYA Females
The 1936 Cohort
UK Biobank
HUNT2
FINRISK
GOYA Males
ALSPAC Mothers
ALSPAC Children
NSHD
Dan-Monica10
SHIP TREND
MIDSPAN
Health2008
COPSAC2000
Subtotal  (I-squared = 0.0%, p = 0.747)
Ever smokers
SHIP
KORA
Whitehall II
Health2006
1958 BC
SHIP TREND
FINRISK
NSHD
UK Biobank
HUNT2
Dan-Monica10
ALSPAC Mothers
GOYA Males
ALSPAC Children
The 1936 Cohort
Health2008
MIDSPAN
Subtotal  (I-squared = 0.0%, p = 0.888)
Study
178
1218
733
1428
1363
2308
1003
61315
201
1275
419
412
19353
9909
2715
279
1397
614
369
1374
351
1063
259
1186
730
514
4106
38296
1400
1238
11241
218
578
217
154
351
209
1225
1174
717
500
202
13344
12617
4567
394
881
274
565
926
214
539
121
131
2599
468
1081
1780
2574
565
8673
1751
51640
23858
1440
2119
611
274
356
339
1117
N
0.75 (0.42, 1.35)
0.79 (0.64, 0.98)
0.89 (0.69, 1.15)
0.89 (0.68, 1.16)
0.91 (0.74, 1.11)
0.94 (0.81, 1.08)
0.95 (0.76, 1.19)
0.98 (0.95, 1.01)
0.99 (0.48, 2.03)
1.01 (0.86, 1.20)
1.04 (0.68, 1.58)
1.07 (0.78, 1.49)
1.03 (0.98, 1.08)
1.09 (1.00, 1.18)
1.09 (0.98, 1.23)
1.12 (0.75, 1.66)
1.11 (0.90, 1.36)
1.09 (0.77, 1.54)
1.28 (0.89, 1.85)
1.00 (0.98, 1.02)
0.81 (0.60, 1.11)
0.88 (0.56, 1.36)
0.86 (0.68, 1.09)
0.94 (0.60, 1.49)
0.94 (0.77, 1.16)
0.98 (0.73, 1.31)
0.93 (0.62, 1.39)
0.99 (0.87, 1.14)
1.00 (0.96, 1.03)
1.02 (0.84, 1.25)
1.03 (0.86, 1.22)
1.02 (0.95, 1.10)
1.01 (0.60, 1.72)
1.08 (0.80, 1.47)
1.09 (0.59, 2.04)
1.08 (0.49, 2.37)
1.00 (0.97, 1.03)
0.56 (0.32, 0.98)
0.70 (0.38, 1.29)
0.83 (0.58, 1.18)
0.81 (0.63, 1.04)
0.87 (0.62, 1.20)
0.88 (0.60, 1.28)
0.94 (0.32, 2.74)
0.94 (0.88, 1.01)
0.96 (0.90, 1.03)
0.97 (0.86, 1.11)
1.03 (0.66, 1.61)
1.08 (0.87, 1.33)
1.14 (0.77, 1.67)
1.09 (0.80, 1.48)
1.09 (0.79, 1.50)
1.13 (0.64, 2.00)
1.10 (0.78, 1.55)
1.14 (0.49, 2.63)
1.41 (0.76, 2.60)
0.96 (0.92, 1.00)
0.80 (0.64, 1.01)
0.86 (0.60, 1.23)
0.86 (0.66, 1.11)
0.87 (0.72, 1.05)
0.92 (0.79, 1.08)
0.96 (0.68, 1.35)
0.98 (0.89, 1.07)
0.98 (0.83, 1.17)
0.98 (0.95, 1.02)
0.99 (0.94, 1.04)
1.03 (0.80, 1.32)
1.04 (0.91, 1.19)
1.05 (0.73, 1.51)
1.14 (0.77, 1.67)
1.06 (0.57, 1.96)
1.07 (0.68, 1.67)
1.11 (0.88, 1.39)
0.98 (0.96, 1.00)
ratio (95% CI)
Odds
  
1.3 .6 2 3
Odds ratio per smoking-increasing allele
Hay fever
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Never smokers
MIDSPAN
Health2008
Dan-Monica10
NSHD
Whitehall II
COPSAC2000
Health2006
GOYA Males
SHIP
NEO
UK Biobank
1958 BC
ALSPAC Children
ALSPAC Mothers
Inter99
ELSA
KORA
HUNT2
FINRISK
The 1936 Cohort
GOYA Females
SHIP TREND
Subtotal  (I-squared = 29.0%, p = 0.101)
Former smokers
GOYA Males
MIDSPAN
ELSA
Inter99
UK Biobank
ALSPAC Mothers
NEO
Health2008
SHIP
Whitehall II
HUNT2
FINRISK
NSHD
Dan-Monica10
Health2006
1958 BC
The 1936 Cohort
KORA
SHIP TREND
Subtotal  (I-squared = 16.0%, p = 0.258)
Current smokers
KORA
NSHD
Inter99
Health2008
Health2006
FINRISK
SHIP TREND
ELSA
NEO
ALSPAC Mothers
UK Biobank
ALSPAC Children
HUNT2
GOYA Males
COPSAC2000
1958 BC
SHIP
Dan-Monica10
Whitehall II
GOYA Females
MIDSPAN
The 1936 Cohort
Subtotal  (I-squared = 2.2%, p = 0.430)
Ever smokers
ELSA
Inter99
GOYA Males
Health2008
NSHD
UK Biobank
FINRISK
ALSPAC Mothers
NEO
Health2006
MIDSPAN
HUNT2
KORA
ALSPAC Children
SHIP
Whitehall II
Dan-Monica10
1958 BC
SHIP TREND
The 1936 Cohort
Subtotal  (I-squared = 23.4%, p = 0.167)
study
1003
279
614
733
1218
412
1363
178
1428
1892
61315
2308
1275
2715
1825
1816
369
19353
13631
201
1488
419
217
578
2606
1347
38296
1238
2778
218
1374
730
11241
5308
1186
514
1063
1400
154
259
351
209
565
1819
121
717
6424
214
841
831
881
13344
274
12617
394
131
1174
1225
926
351
521
539
202
3447
3166
611
339
1751
51640
11732
2119
3609
1780
1117
23858
468
274
2599
1081
1440
2574
565
356
N
0.60 (0.37, 0.97)
0.69 (0.40, 1.22)
0.77 (0.44, 1.34)
0.81 (0.56, 1.16)
0.86 (0.55, 1.35)
0.77 (0.41, 1.43)
0.89 (0.67, 1.17)
0.92 (0.37, 2.27)
0.99 (0.78, 1.26)
0.99 (0.80, 1.22)
1.00 (0.96, 1.04)
1.01 (0.81, 1.26)
1.01 (0.83, 1.23)
1.04 (0.89, 1.21)
1.07 (0.85, 1.35)
1.08 (0.87, 1.34)
1.10 (0.57, 2.13)
1.13 (1.04, 1.22)
1.21 (1.07, 1.36)
1.19 (0.56, 2.54)
1.21 (0.92, 1.59)
1.37 (0.68, 2.75)
1.03 (1.00, 1.06)
0.57 (0.15, 2.15)
0.78 (0.43, 1.39)
0.80 (0.66, 0.96)
0.87 (0.64, 1.18)
0.99 (0.95, 1.04)
1.01 (0.80, 1.27)
1.02 (0.85, 1.24)
0.98 (0.48, 2.01)
1.04 (0.83, 1.32)
1.09 (0.63, 1.89)
1.07 (0.98, 1.18)
1.10 (0.92, 1.31)
1.11 (0.83, 1.48)
1.10 (0.70, 1.73)
1.14 (0.88, 1.49)
1.34 (1.03, 1.75)
1.48 (0.49, 4.44)
1.59 (0.79, 3.23)
1.74 (0.79, 3.82)
1.01 (0.98, 1.05)
0.61 (0.24, 1.55)
0.79 (0.50, 1.25)
0.84 (0.65, 1.08)
0.91 (0.39, 2.12)
0.95 (0.65, 1.38)
0.92 (0.75, 1.13)
0.93 (0.37, 2.35)
0.99 (0.71, 1.38)
1.01 (0.67, 1.51)
1.02 (0.79, 1.32)
1.04 (0.96, 1.13)
1.13 (0.74, 1.73)
1.10 (1.00, 1.20)
1.11 (0.55, 2.23)
2.37 (0.84, 6.68)
1.21 (0.90, 1.65)
1.24 (0.96, 1.62)
1.25 (0.87, 1.80)
1.26 (0.45, 3.47)
1.37 (0.91, 2.04)
1.52 (0.85, 2.73)
2.51 (1.02, 6.15)
1.06 (1.01, 1.11)
0.83 (0.71, 0.98)
0.85 (0.70, 1.03)
0.94 (0.51, 1.74)
0.94 (0.55, 1.61)
1.01 (0.79, 1.28)
1.01 (0.97, 1.05)
1.02 (0.89, 1.16)
1.01 (0.85, 1.20)
1.03 (0.86, 1.22)
1.07 (0.86, 1.33)
1.08 (0.72, 1.63)
1.08 (1.01, 1.15)
1.10 (0.64, 1.92)
1.13 (0.74, 1.73)
1.12 (0.94, 1.33)
1.14 (0.70, 1.85)
1.18 (0.89, 1.57)
1.27 (1.04, 1.56)
1.33 (0.74, 2.41)
1.88 (0.96, 3.67)
1.03 (1.00, 1.06)
ratio (95% CI)
Odds
  
1.3 .6 2 3
Odds ratio per smoking-increasing allele
Asthma
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Never smokers
Health2008
Dan-Monica10
1958 BC
Inter99
Health2006
COPSAC2000
KORA
The 1936 Cohort
I-V Subtotal  (I-squared = 53.9%, p = 0.034)
D+L Subtotal
Former smokers
Dan-Monica10
Inter99
Health2008
Health2006
1958 BC
KORA
The 1936 Cohort
I-V Subtotal  (I-squared = 0.0%, p = 0.845)
D+L Subtotal
Current smokers
The 1936 Cohort
Health2008
1958 BC
Dan-Monica10
Inter99
Health2006
COPSAC2000
KORA
I-V Subtotal  (I-squared = 0.0%, p = 0.769)
D+L Subtotal
Ever smokers
Dan-Monica10
The 1936 Cohort
1958 BC
Inter99
Health2008
Health2006
KORA
I-V Subtotal  (I-squared = 0.0%, p = 0.789)
D+L Subtotal
Study
279
614
2308
1825
1363
412
368
201
514
1347
218
1063
1400
259
154
202
121
1174
926
1819
717
131
208
1440
356
2574
3166
339
1780
467
N
0.69 (0.47, 1.02)
0.88 (0.65, 1.19)
0.88 (0.76, 1.03)
0.99 (0.86, 1.14)
1.04 (0.87, 1.25)
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Figure S8 
Age- and sex- adjusted association of genotype and smoking heaviness.  
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Crude analyses  
Figure S9-S11 
Crude association of smoking status with hay fever, asthma and allergic sensitization. 
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Figure S12 
Crude association of smoking heaviness with hay fever, asthma and allergic 
sensitization
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Figure S13-S15 
Mendelian randomization analysis of the crude associations of rs1051730/rs16969968 and hay fever 
(N=208,365), asthma (N=231,013) and allergic sensitization (N=17,623). 
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Figure S16 
Crude association of genotype and smoking heaviness.  
Overall  (I-squared = 8.9%, p = 0.348)
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Additional analyses 
Figure S17-S18 
Mendelian randomization analysis of the age- and sex- adjusted associations of 
rs1051730/rs16969968 and hay fever and asthma, excluding the UK Biobank data. 
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Figure S19-S20 
Age- and sex- adjusted association of the rs1051730/rs16969968 SNP with hay fever and asthma in 
selected samples of the UK Biobank data. 
 
All
Never
Former
Current
Ever
Persons diagnosed as adults
Never
Former
Current
Ever
Excluding occasional smokers
Never
Former
Current
Ever
Diagnosed as adults, excl. occ. smokers
Never
Former
Current
Ever
Excluding persons from the Bileve Study
Never
Former
Current
Ever
Smoking
61315
38296
13344
51640
56027
35820
12498
48318
61307
28624
10784
39408
56019
26908
10155
37063
41264
25971
6397
32368
N
0.98 (0.95, 1.01)
1.00 (0.96, 1.03)
0.94 (0.88, 1.01)
0.98 (0.95, 1.02)
0.98 (0.95, 1.01)
1.00 (0.95, 1.04)
0.95 (0.87, 1.03)
0.98 (0.95, 1.02)
0.98 (0.95, 1.01)
0.98 (0.94, 1.03)
0.97 (0.90, 1.05)
0.98 (0.94, 1.02)
0.98 (0.95, 1.01)
0.98 (0.93, 1.03)
0.97 (0.88, 1.06)
0.97 (0.93, 1.02)
0.98 (0.94, 1.01)
0.99 (0.95, 1.04)
0.99 (0.90, 1.09)
0.99 (0.95, 1.03)
ratio (95% CI)
Odds
  
1.85 .9 .95 1.05 1.1
Odds ratio per smoking-increasing allele
Hay fever
 
  
59 
All
Never
Former
Current
Ever
Persons diagnosed as adults
Never
Former
Current
Ever
Excluding occasional smokers
Never
Former
Current
Ever
Diagnosed as adults, excl. occ. smokers
Never
Former
Current
Ever
Excluding persons from the Bileve Study
Never
Former
Current
Ever
Smoking
61315
38296
13344
51640
58989
37272
12972
50244
61307
28624
10784
39408
58981
27848
10495
38343
41264
25971
6397
32368
N
1.00 (0.96, 1.04)
0.99 (0.95, 1.04)
1.04 (0.96, 1.13)
1.01 (0.97, 1.05)
0.99 (0.95, 1.03)
0.97 (0.92, 1.02)
1.04 (0.95, 1.14)
0.99 (0.94, 1.03)
1.00 (0.96, 1.04)
1.00 (0.95, 1.05)
1.03 (0.94, 1.12)
1.01 (0.96, 1.05)
0.99 (0.95, 1.03)
0.98 (0.93, 1.04)
1.01 (0.92, 1.12)
0.99 (0.94, 1.04)
1.00 (0.96, 1.05)
0.97 (0.92, 1.03)
1.13 (1.00, 1.27)
1.00 (0.95, 1.05)
ratio (95% CI)
Odds
  
1.9 1.1 1.2 1.3
Odds ratio per smoking-increasing allele
Asthma
 
  
60 
 
Figure S21-S22 
Age- and sex- adjusted association of the rs1051730/rs16969968 SNP with hay fever and asthma, 
excluding the ALSPAC Mothers. 
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Figure S23-S24 
Age- and sex- adjusted association of the rs1051730/rs16969968 SNP with hay fever and asthma, 
excluding the ALSPAC Children. 
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